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GENERAL INTRODUCTION 
Calcium homeostasis is a complex endocrinological process involv­
ing phosphorus, magnesium, parathyroid hormone, calcitonin, and the 
vitamin D metabolites. This homeostatic mechanism is capable of 
maintaining normal blood calcium concentrations under most conditions. 
However, there are certain pathological conditions in which the homeo­
static mechanism is insufficient. One such state is exhibited in the 
periparturient dairy cow - parturient paresis fmilk fever). The 
outstanding clinical features of this syndrome are severe hypocalcemia 
and recumbency. Left untreated, the cow becomes comatose and would 
die. 
The incidence of parturient paresis is greatly reduced by feeding 
cows a low calcium diet the 2 weeks before parturition (Goings e_t £l., 
1974) . Green e£ al. (1981) found that low calcium diets act to 
increase blood concentrations of immunoreactive parathyroid hormone and 
1,25-dihydroxyvitamin D. By stimulating production of these homeo­
static hormones prior to parturition, the calcium demands associated 
with the onset of lactation could be adequately met. However, using 
low calcium diets (< 20 g calcium/day) to prevent parturient paresis 
has not been universally feasible. Therefore, other methods for 
preventing parturient paresis have been sought. 
Since endogenously-produced parathyroid hormone and 1,25-dihy-
droxyvitamin D are capable of preventing parturient paresis, perhaps by 
exogenously supplying the cow with these hormones prior to parturition 
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the physiologic and clinical benefits of a low calcium diet can be 
achieved. In these experiments, the ability of vitamin D metabolites 
and parathyroid hormone to prevent parturient paresis were assessed. 
Dissertation Format 
This dissertation is presented in the alternate thesis format, 
which includes three manuscripts. The paper in Section I is coauthored 
by R. L. Horst, E. T. Littledike, A. Boris, and M. R. Uskokovic, and 
has been accepted for publication in the Journal of Nutrition. The 
papers in Sections II and III are coauthored by R. L. Horst and E. T. 
Littledike. Both are being submitted to the Journal of Dairy Science 
for publication. A review of the literature precedes the first 
manuscript. It is primarily concerned with parathyroid hormone. At 
the end of each section, a separate Literature Cited section has been 
included to facilitate publication. A general Summary and Discussion 
follows the final manuscript. 
The doctoral candidate, Jesse Paul Goff, was the principal 
Investigator in each of these studies. 
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LITERATURE REVIEW 
Calcium Homeostasis 
Intracellular calcium concentration 
Free calcium ion concentration within the cytosol of cells is 
-7 -8 
estimated to be between 10 and 10 M (Kretsinger, 1979). Under 
normal conditions, extracellular fluid calcium ion concentration is 
about 1.2 mM. This means that the extracellular free calcium ion 
concentration Is 10,000 to 100,000 times the Intracellular free 
calcium concentration. Internal calcium ion concentration is pre­
cisely controlled since even minor changes can have wide-ranging 
physiologic, and even pathologic, effects (Carafoli and Pennlston, 
1985). Calcium ions act as a second messenger, relaying electrical 
and chemical messages that arrive at the cell surface to the biochemi­
cal machinery within the cell. Before the implications of changes in 
Intracellular calcium concentration can be understood, it is necessary 
to first discuss how very low calcium ion concentrations within the 
cell can be so precisely maintained against a tremendous concentration 
gradient. Extracellular calcium ions continually leak into the 
cytosolic compartment of the cell through calcium channels located 
within the plasma membrane. There are three mechanisms available for 
removal of calcium ions from the cytosolic compartment of the cell. 
Initially, the free calcium ions can become bound to proteins within 
the cytosol. There are a great number of proteins that are special­
ized for binding calcium within the cytosol; some of them, e.g., 
calmodulin, are important as physiologic messengers in addition to 
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their role in regulating calcium ion concentration (Rasmussen, 1980). 
The capacity of this mechanism for removal of cytosolic calcium is 
very low. The second mechanism is capable of moving many calcium ions 
out of the cytosol. Within the cell membrane there is a protein 
structuré that allows sodium ions outside the cell to be exchanged for 
calcium ions inside the cell. Three sodium ions are brought into the 
cell for every calcium ion extruded. The sodium gradient is the 
driving force for this process. Ultimately, the sodium Jons must be 
+ + 
actively pumped out of the cell by a membrane-bound Na -K -ATPase 
(Carafoli and Penniston, 1985). Third, calcium ions can be pumped 
outside the cell or into cell organelles — in particular, the 
cisternae of the endoplasmic reticulum (sarcoplasmic reticulum of 
muscle) and the mitochondria. This is accomplished by a membrane-
bound Ca -Mg -ATPase (Borle, 1967). As calcium concentrations 
within the cytosol increase, binding sites on calmodulin become fully 
occupied and calmodulin changes its configuration. Calcium-activated 
calmodulin then becomes associated with the Ca -Mg ATPase embedded 
within the membranes, initiating active pumping of calcium from the 
cytosol (Carafoli and Penniston, 1985). 
The mechanisms that remove calcium ions from the cytosol are able 
to compensate for the normal rate of influx of calcium ions into the 
cell from the extracellular fluid so that intracellular calcium ion 
concentration remains unchanged. However, if the rate of entry of 
calcium into the cell changes, the intracellular calcium ion concen­
tration would be expected to change. In some excitable cells. 
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chemical or electrical excitation of the plasma membrane induces an 
increase in the size of the calcium channels, allowing more into the 
cell. In the case of a muscle cell, this triggers contraction. 
However, in most of the cells of the body the calcium channels do not 
appear to be so flexible. Therefore, changes in extracellular calcium 
ion concentrations play a major role in determining the rate of influx 
of calcium into a cell (Carafoli and Penniston, 1985). Cytosolic 
calcium ion concentration in parathyroid gland cells seem to be 
especially sensitive to changes in extracellular calcium ion concen­
tration. 
Parathyroid glands 
The parathyroid glands of mammals, birds, and amphibians arise 
from differentiation of the third and fourth branchial pouches of the 
developing embryo. In mammals, the pair of parathyroid glands arising 
from the third branchial pouch tend to migrate with the developing 
thymus gland. The pair of parathyroid glands arising from the fourth 
branchial pouch migrate with the thyroid primordium (Roth and 
Schiller, 1976). In some species, one pair of parathyroid glands 
fails to develop while in others additional accessory parathyroid 
tissue can be found (Table 1). Fish apparently do not have a parathy­
roid gland (Pang, 1973). 
The histology of the parathyroid gland is similar in all species. 
There is species variation in the amount of stromal fat present, 
vascularity, and amount of fibrous connective tissue, but parathyroid 
hormone (PTH)-producing chief cells of all species are similar, even 
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Table 1. Parathyroid gland location in several species 
Chicken - III and IV (often coalesced together) 
- lie near origin of common carotid arteries 
- caudal or within thyroid 
- occasionally have accessory glands 
Rat, mouse - III only 
- embedded in dorsolateral border of cranial pole 
of thyroid 
- occasionally accessory tissue within the thymus 
- Ill-within carotid sheath anywhere from base of 
tongue to thymus 
- IV-within thyroid gland 
- Ill-within fat cranial, dorsal, and lateral to 
thyroid 
- IV-near or within thymus at bifurcation of 
common carotid artery 
- Ill-within medial surface of thyroid near trachea 
- IV-near common carotid artery near caudal pole of 
thyroid along superior thyroid artery. (Calf 
may surround internal carotid near its origin) 
Sheep and goat - HI-within medial surface of thyroid near trachea 
- IV-near carotid bifurcation, often along sub­
maxillary artery 
Pig - III only 
- within thymus or attached to common carotid 
artery 
Dog - Ill-dorsolateral aspect of thyroid 
- IV-caudal portion of cranial pole of thyroid 
- Accessory glands within thymus are common 
Man - Ill-within inferior pole of thyroid 
- IV-slightly superior to thyroid where middle 
thyroid artery crosses recurrent laryngeal 
nerve 
Rabbit 
Horse 
Cow 
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at the electron microscope level (AltenMhr, 1972; Capen, 1971). 
Oxyphil cells are common in some species and are most common in the 
elderly. Oxyphils are believed to be a degenerated form of the chief 
cell. They are not capable of synthesizing PTH (Hunger and Roth, 
1963). 
PTH biosynthesis 
The mRNA that directs the synthesis of parathyroid hormone codes 
the production of a 115 amino acid peptide (PRE-PRO-PTH) consisting of 
an initiator peptide (2 amino acids), a signal sequence (23 amino 
acids), a pro-component (6 amino acids), and the parathyroid hormone 
(84 amino acids). The entire 115 amino acid sequence never exists as 
such within the parathyroid cell because the peptide is cleaved before 
translation is concluded. The initiator peptide is removed when the 
nascent chain is only 20-30 amino acids long (Habener, 1981a). 
A signal sequence is common to all proteins that are produced by. 
cells for export out of the cell. It facilitates transport of the 
growing peptide from the ribosome surface into the cisternae of the 
rough endoplasmic reticulum (Lingappa and Blobel, 1980). The signal 
sequence is cleaved off the peptide just after translation is com­
pleted. 
The 90 amino acid peptide remaining (PRO-PTH) is transported to 
the Golgi apparatus for further processing. There an enzyme cleaves 
the first six amino acids from the amino terminal end of the peptide, 
converting it to PTH. PTH-(l-84) then is incorporated into membrane-
bound granules where it is stored until secreted. No PRO-PTH is 
8 
thought to be Incorporated into secretory granules (Habener a^., 
1976). Electron microscopists describe two types of secretory 
granules within parathyroid cells (Roth and Capen, 1974). Type I 
granules have a large core relative to vesicle diameter. Type II 
granules are believed to be the storage form of nascent PTH. Type II 
granules have a smaller core. They are the predominant form seen in 
animals under hypercalcemic conditions. They contain some acid 
phosphatase activity indicating the presence of hydrolytic enzymes. 
Type II granules arise from Type I granules (probably after fusion 
with lysosomes) and appear to represent an intracellular method for 
degradation of PTH-(l-84), especially under hypercalcemic conditions 
(Setoguti jet al., 1985a) . 
Up to 70% of nascent PTH-(1-84) is not incorporated into se­
cretory granules within the Golgi apparatus, but is released into the 
cytoplasm (Morrissey £t al., 1980) where it is vulnerable to proteo­
lysis. Most commonly, cleavage occurs between the 33-34 position, but 
cleavage can occur at many sites (Hanley ^  al., 1978). Parathyroid 
glands also possess cathepsin B, which cleaves PTH-(l-84) between 
amino acids 36 and 37 and cathepsin D, which cleaves PTH-(1-84) 
between amino acids 34 and 35 (Cohn and Elting, 1983). 
Amino terminal fragments PTH-(l-29) and PTH-(l-34) are produced 
within the parathyroid cells (Morrissey £t al., 1980). However, they 
apparently undergo rapid intracellular degradation as they cannot be 
detected in venous effluent from parathyroid glands in vivo (Mayer ^  
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al., 1979) nor can they be detected In media in which parathyroid 
cells have been cultured ^  vitro (Morrissey ^  £l., 1980) . 
A major regulatory site for the production of PTH is DNA synthe­
sis leading to multiplication of parathyroid cells. Chronic hypocal­
cemia stimulates hyperplasia of the parathyroid glands with concomi­
tant increases in PTH production (Habener, 1981a). 
Synthesis of new hormone by the parathyroid cells is apparently 
continuous and not a site of regulation. Neither transcription nor 
translation of PTH mRNA is greatly affected by the calcium status of 
the animal (Habener, 1981b) or by the concentration of cyclic AMP 
within the parathyroid cell (Morrissey and Cohn, 1979a). 
Post-translational intracellular degradation of PTH-(l-84) may be 
an important means of regulating the production of biologically active 
PTH within the glands. Intracellular degradation of PTH-(l-84) Is 
stimulated by high extracellular concentrations of calcium, whereas 
low extracellular calcium concentration inhibits intracellular 
destruction of PTH (Habener e^ , 1975; Chu e^ al., 1973). 
Parathyroid glands also produce and release a glycoprotein with a 
molecular weight of around 150,000 known as parathyroid secretory 
protein (Morrissey and Cohn, 1980). Its release from parathyroid 
cells is governed by the same factors that govern PTH secretion. Its 
function is unknown. It has been suggested that parathyroid secretory 
protein is a component of the Golgi vesicle whose extrusion from the 
parathyroid cells is coincidental to PTH secretion (Habener and Potts, 
1979). 
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Peripheral metabolism of PTH 
Circulating immunoreactive PTH consists of a mixture of intact 
PTH-(l-84) and both carboxy- and amino-terminal fragments of 
PTH-(l-84) (Berson and Yalow, 1968). Metabolism of intact hormone by 
peripheral organs contributes greatly to the heterogeneity of the 
circulating PTH (Canterbury et al., 1975). Intravenously injected 
radioiodine-labeled intact PTH-(1-84) is rapidly cleaved by peripheral 
organs, primarily between amino acids 33-34 (Segre et , 1974) and 
36-37 (Segre £t al., 1976), of the PTH molecule. Since the biological 
activity of PTH resides within the first 27 amino acids (Marcus and 
Aurbach, 1969; Parsons et al., 1973; Treagear al., 1973), it is 
likely that cleavage of PTH-(1-84) at these sites can give rise to 
fragments of PTH that are biologically active. The major organs 
involved in the peripheral catabolism of PTH are liver, kidney, and 
bone. 
Fang and Tashjian (1972) observed that the rate of disappearance 
of intact PTH from the plasma was dramatically decreased following 
partial hepatectomy of rats. Canterbury £!• (1975) found that 
isolated perfused rat liver was capable of cleaving PTH-(l-84) to two 
fragments, the amino (NH^)-terminal fragment, retaining full 
biological activity (based on rat renal cAMP production), while the 
carboxy (COOH)-terminal fragment was devoid of activity. They also 
observed that production of the NHg-terminal fragment was inversely 
proportional to the concentration of calcium in the perfusion media. 
More recent evidence suggests that only the intact hormone is taken up 
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by the liver, for there is no arterial-venous difference in 
concentrations of NH2-terminal or COOH-terminal fragments across the 
liver in dogs (Martin et al., 1976). 
An interesting observation is that the hepatic uptake and catabo-
lism of PTH-(l-84) is markedly reduced in chronic renal failure 
(Hruska eJC al., 1981) . 
The Kupffer cells of the liver seem to be the cells responsible 
for cleavage of intact PTH (Segre £t al., 1981). Kupffer cells are 
the macrophages of the liver tissue. 
The kidney also plays a major role in PTH metabolism. Several 
laboratories have reported that intact PTH-(l-84) is degraded by 
kidney tissue in vitro (Chu et al., 1975; Martin et al., 1977). In 
studies of isolated perfused kidney of dogs, it was found that the 
rate of degradation of PTH was accelerated in the presence of hypocal­
cemia and retarded in the presence of elevated calcium concentration 
in the perfusate. Both COOH-terminal and NH2-terminal PTH fragments 
are produced and released into the circulation by the kidney. 
Nephrectomy leads to greatly diminished metabolic clearance rate 
of PTH and PTH fragments (Hruska £t al^., 1981; Martin ^  al• » 1977). 
The studies of Freitag £t al. (1978), Kau and Maack (1977), and Martin 
et al. (1977) were instrumental in the development of the following 
model for renal clearance of PTH as described in a review article by 
Slatopolsky £t a^. (1981). All forms of PTH undergo glomerular 
filtration and tubular reabsorption. The biologically active forms of 
PTH (intact PTH-(l-84) and NHg-terminal fragments) are removed by both 
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glomerular filtration and by uptake from peritubular capillaries 
followed by degradation within renal tubular epithelium. Biologically 
inactive COOH-terminal fragments can only be cleared by glomerular 
filtration. When glomerular filtration rate is decreased, as it is in 
patients with chronic renal failure, the clearance rate of all PTH 
fragments- is greatly decreased. Because NHg-terminal PTH can still be 
removed by tubular cell uptake from peritubular capillaries, the 
relative amount of COOH-terminal PTH in plasma rises faster than does 
NHg-terminal PTH. These COOH-terminal fragments are biologically 
inactive, in terms of calcium homeostasis, but recent reports indicate 
these COOH-terminal fragments, along with the NH2-terminal fragments, 
are potentially toxic in patients with renal failure. Slatopolsky et 
al. (1980) have reviewed some of these effects that include osteitis 
fibrosa, encephalopathy, neuropathy due to brain tissue calcification, 
glucose intolerance, acidosis, hyperlipidemia, and anemia. 
The metabolism of PTH in bone is currently a subject of consider­
able controversy. Many laboratories report that intact PTH-(1-84) is 
removed from the circulation by bone and stimulates resorption of bone 
calcium (Calvo et al., 1985; Goltzman, 1978; Peck e£ al., 1973). 
However, there is a great deal of evidence that indicates that intact 
PTH must be cleaved to an NH2-terminal fragment for complete activity 
in bone. Parsons and Robinson (1968) found that perfusion of bPTH-
(1-84) into the isolated feline tibia nutrient artery had little 
effect on release of calcium from the bone. However, if the bPTH-
(1-84) was first circulated through the whole body prior to infusion, 
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it greatly stimulated calcium release from the bone. Martin et al. 
(1978) reported that isolated perfused canine tibia selectively takes 
up bPTH-(l-3A) but not bPTH-(l-84). They also observed that only 
bPTH-(l-34) would markedly stimulate release of cAMP from the perfused 
tibia. Recently, Sugimoto et al. (1985) developed a system for 
perfusion of isolated rat femora. They conclude that hPTH-(l-34) is 
capable of stimulating cAMP release from bone and that hPTH-(l-84) is 
not. 
Most of the work that ascribes PTH-(l-84) full biologic activity 
in bone has been done using fetal rat calvaria. There is little doubt 
that PTH-(l-84) is capable of stimulating adenylate cyclase in these 
cells in culture. However, Freitag jet al. (1979) suggest that fetal 
rat calvaria first catabolizes PTH-(l-84) to NH2-terminal fragments 
which then activate adenylate cyclase of the cultured cells. Adult 
bone tissue does not seem to be capable of catabolizing intact PTH-
(1-84) (Martin et al», 1978). Therefore, a tissue-age effect may 
account for some of the differences in the activity ascribed to 
PTH-(l-84). Calvo £t al. (1985) reported that PTH-(l-84) was fully 
capable of stimulating skeletal release of cAMP when administered to 
perfused mature rat hindquarters. The model excluded the possibility 
of PTH catabolism by visceral organs but maintained the bone situ. 
These results conflict with those of Sugimoto e_t al. (1985). The only 
difference between the two experiments was the presence of muscle and 
skin in the preparation of Calvo _et aA. (1985). Perhaps the 
PTH-(l-84) was catabolized by this extra-osseous tissue. 
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The relative contribution of bone, liver, and kidney to the 
metabolic clearance of PTH-(1-84) has been calculated in adult dogs by 
determining arteriovenous differences of immunoreactive bPTH-(l-84) 
across these organs. Slatopolsky £t £l. (1981) found that 56% of 
PTH-(1-84) was "cleared" from the blood by the liver, 33% was cleared 
by the kidneys, and bone cleared less than 5% of the PTH-(1-84), 
leaving 6% unaccounted for. 
If PTH-(l-84) requires extraskeletal cleavage to achieve complete 
activity in bone, the peripheral catabolism of PTH-(1-84) secreted by 
the parathyroid glands may represent an activating step rather than 
simply a degradative step. Regulation of liver and kidney metabolism 
of PTH may significantly affect the circulating levels of NHg-Cerminal 
PTH fragments and, hence, the effects of PTH at the level of bone. 
PTH Secretion 
The cells of the parathyroid gland are continuously engaged in 
the biosynthesis, partial degradation, and secretion of PTH. Little 
active product is stored within the cells, in contrast to other 
peptide-secreting endocrine organs. For instance, pancreatic cells 
contain enough insulin to satisfy normal needs for several days, 
whereas PTH reserves do not support normal requirements for more than 
6-7 hours (Martin, 1985). 
The parathyroid chief cells never totally shut down secretion of 
PTH. Individual chief cells seem to maintain a basal level of PTH 
secretion even if exposed to the suppressive effect of a sustained 
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hypercalcemia (Mayer et al., 1979). In the event of sustained hyper­
calcemia, the only way to decrease PTH concentration in the blood is 
to decrease the amount of parathyroid tissue (Habener, 1981a; Mayer 
al., 1976). 
Studies on the effects of different secretagogues on parathyroid 
cells indicate two intracellular pools of PTH are available for 
secretion (Morrissey and Cohn, 1979b). One pool contains newly 
synthesized hormone, whereas the other contains older stored PTH 
(Morrissey and Cohn, 1979b) which may very well correspond to the two 
types of secretory granules that have been observed within parathyroid 
cells (Setoguti £t al., 1985a). 
There are at least two major pathways by which PTH secretion is 
stimulated. The first pathway is mediated by cytosolic calcium ion 
concentration. Early reports indicated that a decrease in cytosolic 
calcium ion concentration stimulates release of PTH from both the 
newly synthesized and the older pool of PTH (Morrissey and Cohn, 
1979b). However, it now appears that low calcium concentration has 
little or no effect on release of the older storage granule pool of 
PTH (Hanley and Wellings, 1985). The second pathway is via changes in 
intracellular cAMP concentrations. Increased cAMP concentrations 
result in secretion of PTH from the older pool of PTH only (Morrissey 
and Cohn, 1979b). Two cAMP-dependent protein kinases have been 
identified within the parathyroid cells which are believed to play a 
role in PTH secretion (Lasker and Spiegel, 1982), but their exact 
function is unknown. 
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Parathyroid hormone is released from the cell by exocytosis. 
Shortly after secretion of PTH, the secretory granule membranes are 
retrieved by endocytosis, presumably for recycling (Wild et al., 
1985). 
Factors Affecting PTH Secretion 
Calcium 
Extracellular fluid calcium ion concentration is the major 
regulator of PTH secretion. Hypercalcemia inhibits, while hypocal­
cemia rapidly stimulates PTH release. Initially, it was felt that 
there was a linear relationship between PTH secretion and extracellu­
lar calcium concentration (Sherwood et al., 1968). Subsequently, a 
sigmoidal relationship was shown to exist between PTH release and 
extracellular calcium concentration (Brown, 1983; Mayer and Hurst, 
1978). This relationship results from the fact that a certain degree 
of PTH secretion is nonsuppressible; i.e., no matter how high the 
extracellular calcium concentration, the chief cells continue to 
secrete a low basal level of PTH. Also, at some low calcium concen­
tration, the chief cells are maximally stimulated. Further reduction 
in calcium does not result in increased secretion of PTH. - There also 
seem to be individual differences in the calcium set-point to which 
the glands respond. The set-point for a parathyroid gland is defined 
as the calcium concentration at which PTH secretion is 50% of maximal 
secretion. Often humans suffering from hyperparathyroidism do not 
have a neoplastic parathyroid, gland. Instead, recent research 
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indicates that these patients simply have parathyroid tissue with a 
higher set-point for calcium than normal. At a blood calcium concen­
tration of 10 mg/dl, a normal parathyroid gland would only be secret­
ing PTH at a rate slightly greater than the basal secretion rate. 
However, glands of a patient diagnosed with hyperparathyroidism will 
often secrete PTH at a rate well above the basal rate at this same 
calcium concentration (Brown, 1983; Insogna et al., 1985). 
Conversely, hypoparathyroidism may in some cases be due to parathyroid 
glands with a low set-point for calcium. 
Neonatal calf parathyroid tissues have a higher set-point for 
calcium than do parathyroids of adult cows (Brown, 1981; Keaton 
al., 1978). Calves also maintain higher plasma calcium concentrations 
than do adult cows (Goff £t , 1982). Heifers almost never develop 
severe hypocalcemia at calving despite the fact that some heifers 
produce more milk than older cows that do develop hypocalcemia and 
paresis. These facts raise the following questions concerning the 
pathogenesis of parturient paresis. Does the calcium set-point for 
PTH secretion decline continuously throughout the life of a cow? If 
so, does the decreased calcium set-point leave the older cow in a 
somewhat hypoparathyroid state? While the heifer may begin secreting 
PTH when her blood calcium concentration falls below 9 mg/dl, perhaps 
the older cow does not begin to secrete PTH until her plasma calcium 
concentration is below 8 mg/dl. This could cause a delay in activa­
tion of those calcium homeostatic mechanisms necessary to prevent 
development of severe hypocalcemia. 
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Magnesium 
Magnesium and calcium are equipotent inhibitors of PTH secretion 
in vitro (Targovik et al., 1971). Although high levels of magnesium 
inhibit PTH secretion, a certain level of magnesium must be present to 
allow PTH secretion (Anast £t al., 1972; Buckle £t al., 1968). Al­
though the effects of hypermagnesemia on PTH secretion are rarely of 
clinical importance, the effects of hypomagnesemia have been impli­
cated in the development of several syndromes, including grass tetany 
of cattle. Grass tetany is a disorder in which clinical signs are 
associated with the rapid development of severe hypocalcemia following 
a prolonged period of hypomagnesemia. Littledike et al. (1983) 
observed inappropriately low PTH concentrations in the blood of cattle 
with grass tetany. They concluded that magnesium deficiency prevents 
PTH secretion which then leads to the development of hypocalcemia and 
clinical signs. 
Sodium and potassium 
•f» 
Parathyroid cells utilize Na /Ca exchange mechanisms to remove 
excessive numbers of calcium ions (Rothstein e^ £l., 1982). Low 
extracellular Na and Na /K -ATPase inhibitors (such as ouabain and 
monensin) impair operation of this system. As a result, calcium ions 
accumulate in the cytosol-inhibiting PTH secretion. High 
extracellular levels of may enhance PTH secretion by stimulating 
+ + 
the Na -K -ATPase pump. 
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Phosphate 
Phosphate was once thought to stimulate PTH secretion. Acute 
intravenous phosphate infusion results in a gradual increase in PTH 
secretion. However, phosphate infusion also causes a decrease in 
plasma calcium concentration, which is the true stimulus for PTH 
secretion since phosphorus infusion does not stimulate PTH secretion 
if normocalcemia is maintained by simultaneous infusion of calcium 
(Sherwood e^ al., 1968). Chronic hyperphosphatemia (as in renal 
failure) is also associated with high plasma PTH concentrations but, 
again, release of PTH is believed to be secondary to the hypocalcemia 
associated with hyperphosphatemia. 
The mechanism by which acute intravenous phosphate infusion 
causes hypocalcemia remains a subject of debate. Hebert et al. (1966) 
felt that the degree of hypocalcemia was proportional to the magnitude 
by which the solubility product for CaHPO^ was exceeded. Markedly 
elevated levels of phosphorus undoubtedly do cause precipitation of 
CaHPO^ salts on body surfaces (Carey al., 1968; Craig, 1959). 
There are other observations that do not support the solubility 
product hypothesis to explain the hypocalcemia associated with phos­
phate infusion. Goldsmith and Ingbar (1966) infused phosphate into a 
patient with hypercalcemia due to malignancy (mammary carcinoma). 
Plasma calcium concentration decreased from 18 mg/dl to 8 mg/dl within 
4 days when infusion was ended. Plasma phosphate then rapidly re­
turned to normal. However, calcium concentration did not begin to 
increase for another 11 days. If calcium had simply been deposited 
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extracellularly on body tissues, it should have returned into the 
plasma compartment once phosphate concentration had returned to 
normal. There are probably several mechanisms involved in the effect 
of phosphate on plasma calcium. First, the phosphate ion ties up some 
of the free calcium in the blood. The reduction in ionized calcium 
then stimulates PTH secretion. Reiss ^  £l. (1970) found that total 
calcium, as well as ionized calcium, decreased during phosphate 
infusion. Other work Indicates that phosphate infusion stimulates 
bone formation by causing alterations In the concentration of calcium 
ion within bone-forming cells (Rasmussen, 1971) or through its re­
ported regulatory role in mineralization (Gllmcher and Krane, 1968). 
There has been little recent work on this subject - despite the fact 
that phosphate is commonly employed to treat hypercalcemia of malig­
nancy and hyperparathyroidism (Scolding, 1985). 
Chronic oral phosphate administration or hyperphosphatemia also 
results in hypocalcemia. The major mechanism is inhibition of renal 
25-hydroxycholecalciferol-la-hydroxylase (Gray £t al., 1977). The 
product of this enzyme, 1,25-dlhydroxyvltamln D, is vital to mainte­
nance of normal plasma calcium concentration, primarily through its 
effects on intestinal calcium absorption. 
Factors that act through cAMP 
Epinephrine, dopamine. Isoproterenol, and other 6-2-adrenerglc 
agonists Increase PTH secretion through their activation of membrane-
bound adenylate cyclase (Blum et. al., 1980). Norepinephrine and 
a-adrenerglc agonists depress cAMP levels and PTH release (Brown et 
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al., 1978). Prostaglandin Eg and secretin also stimulate PTH release 
by activating adenylate cyclase, but this action is independent of 
adrenergic receptors (Habener, 1981a). Prostaglandin Fgct lowers 
adenylate cyclase activity and also activates cyclic nucleotide phos­
phodiesterase to decrease cAMP concentration and reduce PTH secretion 
(Gardner, 1980). Theophylline and other phosphodiesterase inhibitors 
retard cAMP degradation and therefore enhance PTH secretion (Habener, 
1981a). 
Elevated cAMP concentrations stimulate release of PTH from the 
older stored pool of PTH. Because the size of this pool is small, 
cAMP-mediated release of PTH is transient and of short duration 
(Hanley and Wellings, 1985). High plasma calcium concentration can 
prevent activation of adenylate cyclase, but low calcium concentra­
tions do not stimulate adenylate cyclase in the chief cells (Hanley 
and Wellings, 1985). High cytosolic calcium concentration leads to 
formation of calcium-calmodulin complexes that bind to and inhibit 
adenylate cyclase and also stimulate activity of phosphodiesterase 
(Peck and Klahr, 1975). 
The parathyroid glands are innervated by vagal and sympathetic 
fibers; however, their physiologic significance is unknown (Metz ejt 
al., 1978). Some species exhibit diurnal PTH secretory rhythms that 
may be controlled by these nerves (Fischer ^  al., 1982). Setoguti et^ 
al. (1985b) have shown that vagal stimulation (parasympathetic) leads 
to increased conversion of Type I secretory granules to Type II 
secretory granules. 
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Miscellaneous factors 
In vitro studies of cultured parathyroid gland cells have shown 
that 1,25-dihydroxyvitamin D directly inhibits PTH secretion (Chertow 
e£ al., 1975). Cantley £t al. (1985) have indicated that 1,25-dihy­
droxyvitamin D suppresses transcription of pre-pro-PTH mRNA in chief 
cells. Chan £t £l. (1986) have shown this effect is independent of an 
increase in extracellular calcium concentration. 
The inhibitory effects of 1,25-dihydroxyvitamin D on PTH secre­
tion are not seen in hypocalcemic animals (Seshadri £t al., 1985). 
Dietel et (1979) found that 1,25-dihydroxyvitamin D also decreased 
cAMP production within chief cells, which also depresses PTH 
secretion. Since one of the functions of PTH is to stimulate renal 
production of 1,25-dihydroxyvitamin D, inhibition of PTH secretion by 
1,25-dihydroxyvitamin D may represent a negative feedback mechanism to 
control 1,25-dihydroxyvitamin D synthesis. Vitamin Dy and 
24,25-dihydroxyvitamin D3 had no inhibitory effects on PTH secretion 
(Dietel e£ al., 1979). 
Vitamin A (retinol) is capable of stimulating PTH secretion in 
vitro and in vivo (Chertow et al., 1977). Retinoic acid has no effect 
on PTH secretion. Chertow £t al. (1977) felt that vitamin A acts by 
altering the structure of the PTH secretory granule membrane facili­
tating fusion of the secretory granule with the cell membrane. The 
membrane stabilizers, such as hydrocortisone and vitamin E, antagonize 
the effects of vitamin A on chief cells, supporting the theory that 
vitamin A acts on secretory granule membranes. Although the 
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hypercalcemia seen in vitamin A intoxicosis is primarily due to direct 
effects of vitamin A on bone resorption, it is possible that increased 
PTH secretion may also contribute. 
Physiologic Actions of PTH 
Effects on the kidney 
Parathyroid hormone has major physiologic effects on renal 
excretion of minerals and on renal conversion of vitamin D to a 
hormone. 
Phosphate excretion When PTH is administered to a parathy-
roidectomized rat, it results in rapid urinary excretion of phospho­
rus. Normally, about 70-80% of filtered phosphate is reabsorbed in 
the proximal convoluted tubule, a small amount (< 5%) is absorbed in 
the loop of Henle, and the rest is excreted. During phosphorus 
deprivation, almost all the phosphate is reabsorbed (Martin, 1985). 
Parathyroidectomized animals excrete less phosphate than normal 
animals. Parathyroid hormone acts tonically on the kidney to maintain 
a basal level of phosphate excretion. Parathyroid hormone primarily 
inhibits proximal tubule reabsorption of phosphorus (Talmage and 
Kraintz, 1954). This process is mediated by cAMP generated as a 
result of PTH stimulation of adenylate cyclase (Chase and Aurbach, 
1968). The cAMP activates cytosolic and brush border protein kinase 
(Sacktor et al., 1977). Kinne and Schwartz (1978) postulate that 
stimulation of the protein kinase results in phosphorylation of a 
specific phosphate carrier protein which regulates the rate of uptake 
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of inorganic phosphate from the urinary space into the cell. Phos­
phorylation results in inhibition of phosphate reabsorption. 
Kempson e£ al. (1981) found that NAD^ inhibits sodium-dependent 
uptake of phosphorus by tubule brush border membranes. They propose 
that PTH, acting via cAMP, stimulates gluconeogenesis which increases 
the NAD^/NADH ratio. The change in the ratio of NAD^/NADH inhibits 
phosphate reabsorption. The activity of alkaline phosphatase, a renal 
tubular brush border enzyme, is highly correlated with the rate of 
tubule phosphate reabsorption (Kempson et al., 1979). However, 
substances which block the activity of alkaline phosphatase do not 
impair renal reabsorption of phosphorus (Shirazi et al., 1981). 
Therefore, alkaline phosphatase probably plays no role in phosphate 
transport. 
The phosphaturic response to exogenous PTH is impaired in several 
conditions, including vitamin D deficiency (Forte e^ , 1976), 
metabolic acidosis (Beck £t £l., 1975), and phosphate deprivation 
(Steele al., 1976). The mechanism is unknown. It is known that, 
at least in phosphate deprivation, PTH continues to stimulate cAMP 
production (Bonjour and Fleisch, 1980). Bellorin-Font et al. (1985) 
present evidence that in metabolic acidosis the coupling of the 
components of adenylate cyclase is impaired. 
Calcium excretion About 56% of blood calcium is not bound to 
plasma proteins. This fraction is able to cross the glomerulus and 
enter the urinary space. Under normal conditions, 50-55% of the 
filtered load is reabsorbed within the proximal tubule, 30% in the 
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loop of Henle, and most of the remainder is reabsorbed in the more 
distal segments of the nephron. Usually less than 1% of the filtered 
calcium actually ends up in the urine (Sutton and Dirks, 1978). For a 
human this amounts to about 100 mg calcium per day. Parathyroidectomy 
leads to increased loss of calcium in the urine, even if plasma 
calcium is subnormal. Parathyroid hormone decreases urinary calcium 
loss primarily by increasing calcium reabsorption within the ascending 
sections of the cortical loops of Henle with lesser effects on the 
distal convoluted tubules. Parathyroid hormone has no effect on 
calcium reabsorption in the medullary ascending loops of Henle. In 
the proximal convoluted tubules, PTH actually decreases calcium 
reabsorption slightly (Bengele et al., 1980; Bourdeau and Burg, 1980). 
Calcium reabsorption from the proximal tubule is dependent on co-
transport of sodium. Na^-K*-ATPase Inhibitors block the reabsorption 
of both ions. More distally, the calcium reabsorptive mechanism is 
independent and separate from sodium transport (Goldberg e^ al., 
1976). The effects of PTH on calcium reabsorption are primarily 
mediated by cAMP. When dibutyryl cAMP, an analog of cAMP, is adminis­
tered to dogs there is an increase in calcium reabsorption in the 
ascending limb of the loop of Henle and a decrease in calcium reab-
sorption in the proximal tubule (Sutton £l., 1976). 
Parathyroid hormone stimulates synthesis of acidic phospholipids 
within the renal cortex (Farese ^  al., 1980). These acid phospho­
lipids (phosphatidic acid and polyphosphoinositides) increase divalent 
cation partitioning into lipid phases (Green et al., 1980). An 
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increase in the amount of these acid phospholipids in brush border 
membrane vesicles results in an increase in calcium uptake (Humes et 
al., 1981), probably through their action as calcium ionophores within 
the renal tubule membrane. 
Magnesium excretion Administration of exogenous PTH extract 
to man results in renal conservation of magnesium. Parathyroid 
hormone has no effect on proximal tubule handling of magnesium. It 
does increase magnesium transport within the ascending limb of the 
loop of Henle (Shareghi and Agus, 1979). It is unclear whether the 
mechanisms for reabsorption of magnesium and calcium are separate or 
identical. 
Excretion of other substances Parathyroid hormone causes a 
decrease in the amount of bicarbonate ion reabsorbed within the 
proximal tubule (Arruda £t £l., 1977). This effect is not mediated by 
inhibition of carbonic anhydrase (Garg, 1975). Loss of bicarbonate 
contributes to the metabolic acidosis that is a common finding in 
hyperparathyroid people (Slatopolsky e£ al., 1981). 
Parathyroid hormone decreases proximal tubule reabsorption of 
sodium. However, little natriuresis is seen because most of the 
sodium is reabsorbed by more distal segments of the nephron (Wen, 
1974). In man, PTH increases the tubular maximum for glucose trans­
port and increases amino acid excretion (Slatopolsky e^ £l., 1981). 
Renal production of 1,25-dihydroxyvitamin D Renal conversion 
of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D is accomplished by 
renal 25-hydroxycholecalciferol-la-hydroxylase. The activity of this 
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enzyme is closely regulated by PTH and/or plasma calcium 
concentration. Parathyroidectomy results in decreased production of 
1,25-dihydroxyvitamin D (Garabedian et al., 1972). 
Hyperparathyroidism generally results in excessive production of 
1,25-dihydroxyvitamin D (Broadus et al., 1983). Exogenous PTH 
stimulates 1,25-dihydroxyvitamin D production iji vitro (Garabedian et 
al., 1972; Kremer and Goltzman, 1982) and in vivo (Aksnes and Aarskog, 
1980). 
Formation and resorption of bone 
This section of the Literature Review is intended to present a 
brief overview of bone dynamics. Reviews by Jaworski (1984), Parfitt 
(1984), Raisz and Kream (1981), Recker (1983), and Rodan and Martin 
(1981) present current concepts on bone formation and remodeling in 
greater depth. 
In the young animal and in small mammals of short life span, bone 
is in a state of growth. Growth occurs through a process of modeling 
(sometimes referred to as external remodeling) in three areas of the 
bone: the physis, the periosteum, and the endosteum. When bone from 
a young animal is observed under the microscope, one finds that nearly 
all free bone surfaces are actively engaged in either bone formation 
or bone resorption (Parfitt, 1984). Growth in length of a bone is 
achieved through growth of a cartilagenous model within the physis. 
First, chondrocytes proliferate and differentiate, then begin to 
secrete cartilage matrix (Type II collagen). The cartilage cells 
undergo hypertrophy and the cartilage matrix becomes mineralized. 
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Blood vessels from the metaphysis invade the calcified cartilage, 
bringing in osteogenic cells which produce woven bone. The new woven 
bone is resorbed by osteoclasts and the woven bone is replaced by 
lamellar bone (Type I collagen) formed by osteoblasts. Increase in 
width of a long bone occurs by the removal of bone by osteoclasts on 
endosteal surfaces and formation of bone on periosteal surfaces by 
osteoblasts. 
In the adult stage of large long-lived animals, bone ceases 
growth in length and width. However, the bone tissue continues to be 
slowly resorbed and replaced by a process known as remodeling (inter­
nal remodeling). This process is distinct from modeling. In remodel­
ing, old bone is replaced by new bone; in modeling, new bone is added 
to the old bone in the growth process or as a reaction to mechanical 
stress, such as the increase in bone width that occurs with exercise. 
Modeling can lead to loss of bone from old surfaces in response to 
changes in mechanical stress also (such as disuse). 
As bone tissue ages, it becomes more mineral dense. It is more 
brittle than young bone and the calcium within the bone is bound more 
tightly to the collagen, making it less available to meet calcium 
homeostasis needs. Remodeling is a bone replacement mechanism which 
functions to prevent the accumulation of fatigue damage in the skele­
ton and to maintain an adequate supply of young bone of relatively low 
mineral density to subserve mineral homeostasis. When adult bones are 
observed histologically, only about 20% of the trabecular (cancellous) 
bone surface and about 5% of .the Intracortical bone surface are active 
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with respect to bone remodeling (Parfitt, 1984). The next sections of 
this review will focus on the mechanisms of bone resorption and 
formation during the remodeling processes in trabecular and cortical 
bone. 
Cancellous bone" remodeling The normal sequence of events 
during remodeling begins with activation of a quiescent site on the 
trabecular surface of cancellous bone. In the quiescent stage, 
trabeculae are lined by endosteal lining cells. They probably are 
deactivated osteoblasts (Parfitt, 1984; Rodan and Martin, 1981). They 
differ from active osteoblasts in that they are flattened and appear 
to have lost their ability to synthesize collagen (Parfitt, 1984). 
Initiating remodeling requires the recruitment of osteoclasts, a means 
for them to gain access to the bone, and a mechanism for their attach­
ment to the bone surface. The site chosen for bone remodeling seems 
to be random, although focal structural damage is also a likely 
initiator of remodeling. The events involved in activation of 
remodeling are not well understood. They will be discussed later in 
the review. 
Once the osteoclasts have made contact with the bone, they begin 
to erode a cavity within the bone. This cavity is known as a 
Howship's lacuna. Generally, the mean depth of the lacuna is 60 pm 
from the surface of the trabecula. The area covered by the lacuna 
seems to be dependent on the number of nuclei incorporated into the 
osteoclasts. In trabecular bone, osteoclasts rapidly erode the first 
two-thirds of the lacuna cavity. They then disperse (or die) and the 
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remainder of the cavity is eroded slowly by extracellular enzyme 
products left by the osteoclasts and by mononuclear cells that have 
followed the osteoclasts into the cavity (Ericksen £t al., 1983)• The 
mononuclear cells could be bone-resorbing monocytes or, more likely, 
they could be mononuclear osteoclast precursors that have failed to 
fuse with the osteoclast. 
How the depth of the lacuna is determined is unknown. Several 
possible controls have been postulated. The simplest explanation is 
that osteoclastic activity ceases when the nuclei within the 
osteoclast live out their life span and no new nuclei are recruited. 
However, recently prostacyclin has been shown to inhibit osteoclast 
motility and bone resorption (Parfitt, 1984). Osteoblasts have been 
implicated as cells that might produce prostacyclin to modulate 
osteoclast activity. 
While the osteoclasts are burrowing into the trabecular surface, 
the process of bone formation is beginning to fill in the space 
created by the osteoclasts. First, mononuclear cells (which may be 
pre-osteoclasts or pre-osteoblasts) clean up cellular debris left by 
the osteoclasts. They smooth the lacuna surface and then secrete a 
thin layer of highly mineralized, but collagen-poor, bone matrix 
(cement substance) which prepares the surface for bone formation. 
Osteoblast precursors then begin to multiply along the cement line. 
The stimulus for this division is unknown. Local bone growth factors, 
such as skeletal growth factor, are believed to play a role (Farley ^  
al., 1982).. Plump, round osteoblasts eventually line the surface of 
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the cement substance and begin to secrete collagen and the other 
components of bone matrix. If there is an adequate supply of calcium 
and phosphate present, mineralization of the matrix occurs once the 
matrix has matured. Details of the mineralization process are contro­
versial and will not be discussed here. 
During active formation of bone, the osteoblasts are separated 
from the mineralized matrix by unmineralized matrix (osteoid). This 
osteoid seam eventually disappears as mineralization catches up with 
the osteoblast once the lacuna has been filled with osteoid. [In 
osteomalacia (adult rickets), much of the osteoid never is mineralized 
due to lack of calcium, phosphate, and/or vitamin D.] As the matrix 
surrounding the nonmotile osteoblast becomes mineralized, the osteo­
blast is converted to an osteocyte. As bone formation proceeds, 
eventually the lacuna is entirely filled with bone. Once level with 
the original trabecular surface, the osteoblasts revert to a quiescent 
flattened form that lines the trabecular surface. Some authors refer 
to them as "lining cells" at this stage. Once again, they are inac­
tive until bone remodeling is activated in that site. In the human, 
this occurs about every 7 years (Martin, 1985). The extent to which 
the lacunae are refilled is probably more highly dependent on the 
number of osteoblasts recruited into the area than on the biosynthetic 
activity of an individual osteoblast (Parfitt, 1984). Hormonal agents 
that regulate bone formation probably act more on osteoblast recruit­
ment than on osteoblast function (Jaworski, 1984). This has 
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especially important implications for bone disease states such as 
osteoporosis. 
Cortical bone remodeling Lamellar cortical bone is found 
under the periosteum and articular surfaces of all bones. It is very 
dense and compact. In many respects, remodeling of lamellar bone is 
similar to remodeling of trabecular bone. Both require some 
activation factor that causes quiescent bone surface to become active. 
In both cases, old bone is attacked by osteoclasts and replaced by 
osteoblasts. The net result is replacement of old bone with new, more 
structurally sound bone in both areas. 
However, there are important differences. In trabecular bone, 
the endosteum is adjacent to the hematopoietic system which serves as 
a source of pre-osteoclasts and monocytes. To begin remodeling of 
periosteal or articular surfaces of lamellar bone, the pre-osteoclasts 
and monocytes must move to the activation site via the capillaries. 
Once at the site of remodeling, the osteoclastic precursors fuse into 
giant multinucleated osteoclasts and begin resorbing bone. This 
resorbing process is similar to that in trabecular bone except that on 
average the depth of the lacunae "drilled out" by the osteoclasts is 
deeper (100 um) and more cylindrical in shape. In lamellar bone, 
these lacunae outline the Haversian system that is easily recognized 
in histologic sections of bone. As the osteoclasts drill into the 
bone, bone-lining cells and mononuclear cells migrate into the lacuna 
along the bone just behind the osteoclasts, just as in trabecular 
bone. The mononuclear cells may play an important role in regulating 
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the osteoclastic activity as well. Mundy (1983) lists possible 
mechanisms by which the mononuclear cells may affect bone resorption. 
These include production of prostaglandin E^, osteoclast-activating 
factor (OAF), and interleukin I which act to stimulate bone 
resorption. In addition, the mononuclear cells may be precursors for 
the osteoclasts. 
As the bone-lining cells follow the osteoclasts, they lay down 
cement substance along the surface of the lacunae. Then some of them 
differentiate into osteoblasts which begin to secrete collagen and 
form bone at a right angle to the direction in which the osteoclasts 
have "drilled." The lacunae then is filled in from the outer wall 
towards the center (Jaworskl, 1984). An analogy is to think of 
drilling a hole into a piece of wood, then having the wood grow back 
into the hole from the new surface created by the drill toward the 
center of the hole. 
Hormonal control of bone resorption 
A number of hormones are known to stimulate calcium release from 
bone both ^  vitro and Im vivo. These bone-resorbing hormones Include 
PTH, 1,25-dihydroxyvitamin D, and prostaglandins. One might expect 
that these substances would act directly on osteoclasts.to stimulate 
bone-resorbing activity. However, no one has been able to demonstrate 
receptors for PTH or 1,25-dihydroxyvitamin D in osteoclasts. Chambers 
et al. (1985) have found that the direct effect of prostaglandin is 
to actually decrease bone resorption by osteoclasts. 
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Parathyroid hormone and 1,25-dihydroxyvitainln D receptors have 
been demonstrated in osteoblast cells of bone (Rodan and Martin, 
1981). Activation of PTH receptors on osteoblasts results in stimula­
tion of adenylate cyclase activity, resulting in a cAMP surge, rapid 
activation of cAMP-dependent protein kinase, inhibition of collagen 
synthesis, inhibition of alkaline phosphatase activity, stimulation of 
calcium uptake, and production of changes in cell shape of the osteo­
blast. The osteoblastic response to 1,25-dihydroxyvitamin D is 
transcriptional inhibition of collagen synthesis and decreased alka­
line phosphatase activity. In addition, 1,25-dihydroxyvitamin D can 
inhibit the replication of bone cells under some conditions (Raisz, 
1984). 
It is difficult to understand how these hormones act. In the 
case of 1,25-dihydroxyvitamin D, it is well documented that it is 
necessary for normal bone growth, yet it inhibits bone collagen 
synthesis ^  vitro. Raisz (1984) attempts to reconcile these incon­
gruities. He feels that 1,25-dihydroxyvitamin D acts as a bone growth 
factor only at low concentrations, when calcium and phosphorus are 
abundant. Under these circumstances, it permits growth. When calcium 
and phosphate are in short supply, the synthesis of 1,25-dihydroxy­
vitamin D increases greatly, blocking osteoblast synthesis of bone 
collagen - which probably could not calcify properly until blood 
calcium and phosphate had returned to normal anyway. 
Rodan and Martin (1981) proposed the following hypothesis to 
explain how hormones that act directly on osteoblasts can stimulate 
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bone resorption by osteoclasts. According to this hypothesis, in 
quiescent bone inactive osteoclasts are separated from the bone by a 
contiguous layer of inactive osteoblasts. These osteoblasts are 
flattened and completely cover the surface of the bone. Rone-
resorbing hormonal agents, such as PTH and some prostaglandins, induce 
(via cAMP or calcium flux) a shape change in the osteoblasts. As the 
osteoblasts retract, the matrix beneath them is uncovered, exposing it 
to osteoclasts or osteoclast projections. The idle osteoclast is 
stimulated to begin resorbing bone simply by exposure to bone matrix. 
The resulting matrix digestion further enhances resorption by releas­
ing collagen and osteocalcin locally which attracts monocytic osteo­
clast precursors and idle osteoclasts to the site. A second aspect is 
the direct activation of osteoclasts by products of hormone action on 
osteoblasts. Osteoblasts may produce osteocalcin or prostaglandins 
that contribute to the activation of the osteoclasts. Activity of the 
osteoclasts ceases when the osteoblasts are no longer stimulated by 
the bone-resorbing hormones or by the direct action of calcitonin on 
the osteoclasts. Calcitonin receptors have been demonstrated on 
osteoclasts and their activation increases adenylate cyclase activity 
within the osteoclasts and decreases bone resorption mechanisms. 
Although many aspects of this hypothesis remain to be tested, it does 
seem to be the best hypothesis based on the information at hand. 
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SECTION I. 
BONE RESORPTION, RENAL FUNCTION, AND MINERAL 
WITH 1,25-DIHYDROXYCHOLECALCIFEROL AND ITS 
STATUS IN COWS TREATED 
24-FLUORO ANALOGUES 
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INTRODUCTION 
Parturient paresis is a syndrome seen in dairy cows that develop 
severe hypocalcemia at the onset of lactation. Nonparetic cows meet 
the periparturient calcium demand by adequately increasing the amount 
of calcium entering the blood from the diet and from bone. Paretic 
cows do not. Both groups of cows respond to the calcium drain with 
increased parathyroid hormone (PTH) (Mayer et al., 1969) and 1,25-dl-
hydroxyvitamin D3 [1,25-COH)2D3.] (Horst et al., 1978). However, in 
the paretic cows this homeostatic response does not activate bone 
resorptive and intestinal calcium absorption mechanisms in time to 
meet the lactational drain of calcium, possibly because of delayed 
target organ responsiveness. To effectively prevent parturient 
paresis, bone resorption and intestinal absorption of calcium and 
inorganic phosphorus should be stimulated before "paresis-prone" cows 
become hypocalcemic. This can be done by feeding low calcium diets 
prior to parturition (Goings e_t a]L., 1974; Green £t £l., 1981), but 
the management required to maintain cows on these diets has proven 
impractical for many producers. 
The use of the vitamin D family of compounds in the prophylaxis 
of parturient paresis has been of interest for some time. The prophy­
lactic regimes using the parent compound, vitamin D, require the use 
of near-toxic doses of vitamin D (10-20 x 10^ lU), and are only 
effective when given within a precise time period prior to parturition 
(Hibbs and Pounden, 1955; Julien et al., 1977; Littledlke and Horst, 
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1982; Manston and Payne, 1964). When relatively nontoxic doses of 
vitamin D are used (2.5-5 x 10^ lU), they are found to be ineffective 
and actually increase the incidence and severity of milk fever 
(Littledike and Horst, 1979). The elucidation of the vitamin D 
endocrine system and the availability of potent vitamin D metabolites 
renewed the search for an agent capable of preventing parturient 
paresis. 25-Hydroxycholecalciferol (Jorgensen e^ al., 1978; Olson et 
al., 1972), la-OHDg (Barlet, 1977; Sachs et al., 1977; Sansom et al., 
1976; Wittwer and Ford, 1978), and 1,25-(0H)2D3 (Cast £t al., 1979; 
Hoffsis et. » 1978) have been used with some success. These 
compounds have the advantage of a shorter biological life than vitamin 
D; therefore, toxicity problems are reduced. However, the shorter 
biological life also requires a more accurate prediction of the time 
of parturition for full effectiveness. A synthetic vitamin D 
metabolite with a longer biologic activity than 1,25-(0H)2D3 could 
better accommodate inaccuracies in predicting the time of parturition, 
while compromising only slightly on possible toxicities. 
Several workers have shown that 24,24-F2-l,25-(0H)2D3 has greater 
biologic activity than 1,25-(0H)2D3 in rats (Okamoto £t al., 1983) and 
chicks (Corradino e£ al., 1980). The biologic activity of 24-F-
1,25-(0H)2D3 has not been determined for any species, but, based on 
its similarity to 24,24-F2-l,25-(0H)2D3 it might also be expected to 
be more potent than 1,25-(0H)2D3. The present report demonstrates the 
relative potencies of 1,25-(0H)2D3, 24-F-l,25-(0H)2D3, and 24,24-F2-
1,25-(0H)2D3 in nonlactating, nonpregnant adult dairy cows by 
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comparing the effects on plasma mineral concentrations, bone resorp­
tion, and renal excretion of calcium and phosphorus. In addition, we 
present evidence that renal function is impaired following administra­
tion of these compounds. 
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MATERIALS AND METHODS 
Vitamin D Compounds 
The 1,25-(0H)2D3, 24-F-1,25-(0H)jOg, and 24,24-F2-l,25-(0H)2D3 
were supplied from Hoffmann-La Roche, Inc., Nutley, NJ. 
Animals 
Mature (> 3 years of age) nonlactating, nonpregnant Jersey cows 
that had been fed the experimental diet for at least 1 month were used 
in these experiments. Animals were housed indoors in individual 
stanchions during the trials. 
Diet 
Each cow was fed 10 kg of a diet composed of 50% alfalfa hay 
cubes and 50% beet pulp-based commercial supplement (Sweet and Bulky, 
Wayne Feeds Division, Continental Grain, Chicago, IL) per day. The 
calculated daily intake of minerals (calcium, 75 g; phosphorus, 40 g; 
magnesium, 25 g) was well above the NRC requirement (National Research 
Council, 1978). 
Design 
Treatment trials were run for each of the 3 compounds [24-F-
1,25-(0H)2D3, 24,24-F2-I,25-(OH)2D3, and 1,25-(0H)2D3] at the follow­
ing three doses; 25 yg, 100 ug, 400 yg, thus resulting in 9 treatment 
groups. In addition, a tenth group of cows received drug vehicle only 
(ethanol). Each treatment group consisted of 3 cows. 
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Protocol 
A Foley catheter was placed into the bladder of each cow, and 
urine collections were begun 24 hours later. Urine was collected into 
vessels containing 100 ml glacial acetic acid which brought the pH 
between 4 and 5. Daily blood and total urine collections were made 
for the next 4 days to obtain baseline physiologic data for each 
individual cow during this pretreatment period. Plasma and urine 
samples were kept frozen at -19°C until analyzed. 
At the start of day 5, a specific dose (calibrated by ultraviolet 
absorption, = 264 nm, Z = 18,200) of one of the three compounds 
dissolved in 1 ml of ethanol was administered intramuscularly. Daily 
blood and total urine collections were then continued over a 9-day 
posttreatment period to determine the influence of drug treatment on 
various physiologic parameters. 
Physiologic Parameters Monitored 
Daily concentrations of calcium and magnesium in plasma and urine 
were determined for each cow by atomic absorption spectrophotometry 
(Perkin-Elmer Corp., 1965). Plasma and urine inorganic phosphorus 
concentrations were determined colorimetrically (Fiske and Subbarrow, 
1925). 
Concentrations of hydroxyproline in plasma and urine were moni­
tored daily as an estimate of bone resorption activity (Dull and 
Henneman, 1963). Free plasma hydroxyproline and total urinary 
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hydroxyproline were determined colorlmetrically (Bannister and Burns, 
1970; Kiviriko et,±1-» 1967). Renal function was assessed by monitor­
ing urine specific gravity and renal glomerular filtration rate (GFR). 
Glomerular filtration rate was estimated by determining endogenous 
creatinine clearance rates. Plasma and urine creatinine concentra­
tions were determined colorimetrically on an AutoAnalyzer (Chasson £t 
al., 1961). 
The hydration state of the animals was estimated by measuring 
total plasma protein using a refractometer (American Optical Company, 
Buffalo, NY). In addition, plasma glucose and g-hydroxybutyrate 
concentrations were measured by colorimetrlc assays (Trinder, 1969; 
Zivin and Snarr, 1973) to give some indication of the metabolic state 
of the animals throughout the experiment. 
Analysis 
Pretreatment (baseline) and posttreatment samples were obtained. 
The 9 days after treatment were divided into four 2-day periods and a 
single 1-day period to more accurately assess the duration and inten­
sity of the drugs' effects. For each physiologic parameter, the 
effect of the drug was expressed as a percentage of the baseline value 
obtained during the pretreatment period, allowing each cow to act as 
its own control. The means of each group of treated cows were sub­
jected to ^ -tests (LSD) (Barr et , 1976), comparing them to the 
means obtained from the ethanol-treated cows. 
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RESULTS 
All three compounds effectively elevated plasma calcium and 
inorganic phosphorus concentrations at the 100 and 400 pg doses 
(Tables 1 and 2). The 24,24-F2-l,25-(0H)2D3 compound was approxi­
mately 4 times as effective as 1,25-(0H)2D3 in elevating plasma 
calcium and inorganic phosphorus concentrations based on the observa­
tion that 100 pg of 24,24-F2-1,25-(0H)2D3 and 400 ug of 1,25-(0H)2D3 
resulted in similar plasma calcium and inorganic phosphorus concentra­
tions. The 24-F-l,25-(0H)2D3 compound appears to be only slightly 
more effective than 1,25-(0H)2D3 in elevating plasma calcium and 
inorganic phosphorus concentrations. At the 400 yg dose, both the 
fluorinated compounds induced significantly elevated plasma calcium 
concentrations for a longer period of time than did 1,25-(0H)2D3 (Fig. 
1). Administration of any one of the three compounds resulted in 
similar decreases in plasma magnesium concentration. 
Plasma hydroxyproline concentrations were not significantly 
affected by 25 yg or 100 yg of any of the compounds. At the 400 yg 
dose, the 24-F-l,25-(OH)2D3 compound significantly depressed plasma 
hydroxyproline concentration when compared to the effects of ethanol. 
The 400 yg dose of 1,25-(0H)2D3 and 24,24-F2-l,25-(0H)2D3 had no 
significant effect on plasma hydroxyproline concentration. Urinary 
hydroxyproline excretion rate exhibited the same pattern as plasma 
hydroxyproline concentration (Table 3), except that hydroxyproline 
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excretion via the urine was depressed significantly following the 400 
Ug dose of all three compounds. 
Total plasma protein, plasma glucose, and plasma B-hydroxy-
butyrate were not significantly affected by treatment with any of the 
compounds. 
Urine specific gravity was reduced following administration of 
any of the compounds. Isosthenuria (Sp. gr. S 1.012 and > 1.008) was 
seen in most cases, although several of the cows that received 400 yg 
of 24,24-F2-1,25-(0H)2D3 or 1,25-(0H)2D3 were hyposthenuric (Sp. gr. 
5 1.008) for several days. 
The GFR was significantly reduced by all three compounds at the 
400 yg dose and in cows that received 100 ug of 24,24-F2-l,25-(0H)2D3 
(Table 4)• The depression of GFR induced by 400 yg of the fluorinated 
compounds persisted longer than the depression in GFR induced by 400 
Ug of l,25-(OH)2D3• The GFR of the cows was determined again 1 month 
after the end of the experimental period and had returned to pretreat-
ment levels in all cases. 
Urinary calcium excretion rates (Table 5) exhibited a consider­
able degree of variation, as shown in the control cows. There was 
generally an increase in urinary calcium excretion after treatment 
with 25 or 100 ug of the drugs. However, urinary calcium excretion 
rates at the 400 yg dose were less than those seen at the 100 yg dose 
for all three drugs. In addition, the 400 yg doses of 1,25-(0H)2D3 
and 24,24-F2-l,25-(0H)2D3 were associated with lower urinary calcium 
excretion rate than those determined in.the pretreatment periods. 
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Urinary phosphorus excretion rates were also generally increased 
by treatment with any of the compounds. There was considerable 
variation among the cows, which made statistical inferences difficult. 
Assuming that 56% of plasma calcium and all plasma phosphorus is 
filterable across the renal glomeruli, the resting renal tubular 
reabsorption rates (TR) for calcium and phosphorus were estimated 
using the following formulae: 
TR (Ca) = (GFR x [plasma Ca x 0.56]) - (urine vol. x [urine Ca]) 
TR (P) = (GFR x [plasma P]) - (urine vol. x [urine P]). 
Reabsorption of calcium by the renal tubules ranged between 95 and 98% 
efficient. No significant difference was found in renal tubular 
reabsorption rate for calcium or phosphorus after administration of 
any of the compounds studied^ 
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DISCUSSION 
The addition of fluorine to the 24-carbon of the side-chain 
increases the duration and intensity of the hypercalcemic and hyper­
phosphatemia activity of 1,25-(0H)2D3. We found the 24,24-F2-l,25-
(OHOzDs compound to be approximately 4 times as active as 1,25-
(0H)2D3, while the 24-F-l,25-(0H)2D3 compound was intermediate in its 
ability to raise plasma calcium concentrations. Okamoto et al. (1983) 
and Corradino et. fJL" (1980) reported similar findings in experiments 
with 24,24-F2-1,25-(0H)2D3 in rats and chicks. 
Urinary hydroxyproline excretion has been utilized as a sensitive 
index of bone resorptive activity in cattle (Black and Capen, 1971). 
Hoffsis ejt (1978) reported that 600-ug injections of 1,25-(0H)2D3 
to dairy cows caused significant increases in urinary hydroxyproline 
excretion when expressed as a ratio to urinary creatinine. However, 
we could not demonstrate any increase in total urinary hydroxyproline 
excretion with 1,25-(0H)2D3 or the fluorinated analogues. We found 
that the higher doses of the compounds tested actually inhibited 
urinary hydroxyproline excretion. 
The discrepancy in results may reflect the manner in which the 
data was presented. However, we have demonstrated that high doses "of 
any of the compounds tested are capable of dramatically decreasing 
GFR, so urinary hydroxyproline excretion may not be the best indicator 
of bone matrix catabolism in animals with compromised renal function. 
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Plasma hydroxyproline concentration is also a useful indicator of 
bone resorption, activity and is less likely to be affected by reduced 
renal function than urinary hydroxyproline excretion rates. Although 
reduced GFR might result in higher plasma hydroxyproline, we measured 
plasma hydroxyproline concentrations and found no significant change 
with any of the compounds tested. Likewise, Hove al. (1983) and 
Bar £t £l. (1985) found that administration of la-OHDg, 1,25-(OH)2D3, 
1,24,25-(0H)3D3, and 1,25,26-(0H)3D3 to mature cows either had no 
effect or caused a slight reduction in plasma hydroxyproline concen­
tration. Therefore, bone calcium resorption probably has little or no 
role in the hypercalcemia activity observed when pharmacologic doses 
of cholecalciferol compounds are administered to normocalcemic cows. 
The compounds tested induced acute transient changes in renal 
function manifested by an inability to concentrate the urine and a 
reduction in GFR. The hypercalcemia activity of the three compounds 
may be responsible for the observed rena] Insufficiencies. Hypercal­
cemia has long been known to alter the ability of the kidneys to 
concentrate the urine (Lee e_t ^1., 1978; Osborne and Stevens, 1977; 
Schwartz and Relman, 1967). Mechanisms proposed include a blockade of 
the activity of anti-diuretic hormone at the level of the collecting 
ducts (Manitins et al., 1960) or a defect in sodium transport in the 
loop of Henle (Epstein £t £l., 1959). 
Hypercalcemia has also been observed to result in a reduction of 
GFR. There are believed to be two mechanisms at work. Hypercalcemia 
can result in calcification of renal tubules and loss of functional 
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nephron mass (Capen al., 1966; Ganote ££ , 1975). The loss of 
these nephrons is presumably permanent. Hypercalcemia has also been 
shown to cause significant alterations in renal hemodynamics. Calcium 
ions potentiate the vasoconstrictive activity of angiotensin II on 
renal afferent arterioles, thus reducing renal blood flow and GFR 
(Levi £it £l., 1983) . This effect is reversible once normocalcemia is 
established. 
Vitamin D sterols have also been incriminated as the direct cause 
of reduced renal function. Dinkel (1966) showed that nephrocalcinosis 
could be caused by dihydrotachysterol administration despite the 
presence of hypocalcemia. Morrissey £t al. (1977) found renal calci­
fication occurred in chicks fed varying amounts of 25-OHD at dose 
levels lower than those required to induce hypercalcemia. Hartenbower 
£t £l. (1977) suggested that 1,25-(0H)2D3 has a specific toxic effect 
on the kidney since the pattern of calcification of the kidney in rats 
following 1,25-(0H)2D3 intoxication differs from that occurring in 
vitamin D toxicity. 
We could not discern the extent of any direct contribution that 
the compounds tested had on reduction of GFR. However, we have shown 
that the fluorinated compounds produced greater changes in GFR than 
did 1,25-(0H)2D2 at the same doses. 
Initially, the compounds induced hypercalcemia and hypercal-
ciuria. However, as the degree of renal insufficiency increased the 
amount of calcium excreted in the urine decreased, despite greater 
plasma loads of calcium. Therefore, the inability to excrete calcium 
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in the urine appropriate to the plasma load of calcium actually adds 
to the hypercalcemia. Hoffsis £it al. (1978) reported that urinary 
calcium excretion rates of cows were increased by administration of 
1,25-(OH)2D3, but that the changes in urine calcium did not correlate 
directly with the intravenous dose of steroid. Cows in their experi­
ment may have had compromised renal function at the high doses of 
1,25-(OH)2D3, accounting for the lack of a direct correlation between 
urinary calcium excretion and steroid dose. Kopple and Coburn (1973) 
noted that even mild to moderate renal insufficiency can be associated 
with lower than normal urinary calcium excretion. 
Vitamin D compounds can induce hypercalcemia and hyperphospha­
temia by increasing intestinal calcium and phosphorus absorption, 
increasing bone resorption, or by decreasing the loss of calcium and 
phosphorus via the urine. In this experimental model, the compounds 
tested did not act by stimulating bone resorption or by inducing renal 
conservation of calcium and phosphorus over control animals. The 
hypercalcemia and hyperphosphatemia caused by the compounds tested are 
probably the result of stimulation of active transport mechanisms for 
calcium and phosphorus within the intestinal tract (Braithwaite, 1980; 
Hove, 1984). 
The 24-F-1,25-(0H)2D3 and 24,24-F2-l>25-(OH)2D3 compounds have 
equal or greater biopotency than 1,25-(0H)2D3 in all physiologic 
parameters we measured. Okamoto ejt al. (1983) suggest that fluorine 
atoms on the 24-carbon block hydroxylation which may be necessary for 
inactivation of the compound, thus prolonging the biological activity. 
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In this study, we have found that the prophylactic activity of 
the compounds tested would reside mainly in their ability to markedly 
increase intestinal calcium and phosphorus absorption. Further 
studies must capitalize on this beneficial effect while minimizing the 
potentially harmful effects of these compounds which include reduced 
renal function and inhibition of bone resorption activity. 
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Figure 1. Plasma calcium concentrations following a 400-yg dose of 
either 1,25—(OH)zDa» 24-F-l,25-(OH)2D3 ov 24,2A-F2-I>25-
(0H)2D3. Mean ± SEM. *Denotes significantly increased 
plasma calcium concentration above baseline. Period 1 = 
days 1 and 2; Period 2 = days 3 and 4; Period 3 = days 5 
and 6; Period 4 = days 7 and 8; Period 5 = day 9 
Table 1. Plasma calcium concentration during the 5 posttrpatment periods 
expressed as a percentage of pretreatment calcium concentration 
% of Pretreatment Level^ 
Period 1 Period 2 Period 3 Period 4 Period 5 
Treatment (Days 1&2) (Days 3&4) (Days 5&6) (Days 7&8) (Day 9) 
Ethanol 
Control 101.1 
(9.55 ± 0.13) ± 2.0 
24-F-l,25-(0H)2D3 
102.4 
±  0 . 8  
99.6 
± 0,6 
101.1 
+  ]  . 1  
98.8 
± 1.4 
25 Jig 103.4 
(9.24 ± 0.23) ± 2.6 
100 pg 107.4 
(8.36 ± 0.13) ± 1.4 
109.1 
±  0 . 8  
113.2^ 
± 2.5 
101.4 
± 1.5 
110.2' 
± 1.6 
106.2 
± 1.1 
109.7* 
± 1.0 
ND 
ND 
400 Jig 124.3 124.0 123.0 120.4 1 1 7  R  
400 pg 124.3 124.0 123.0 120.4 117.8 
(8.68 ± 0.23) ± 5.9 ± 4.4 ± 3.6 ± 4.5 ± 4.6 
24,24—F 2~1» 25— (0H)2D3 
25 ug 
* 
111.3 
•k 
110.9 106.5* 104.4 ND 
(9.29 ± 0.14) ± 3.6 ± 4.4 ± 5.4 ± 3.4 
100 yg 119.9*^ 
* 
117.] * 115.1 
* 
112.8 111.9 
(8.91 ± 0.24) ± 1.9 ± 2.5 ± 4.7 ± 3.2 ± 6.6 
400 wg 
* 
129.3 139.9 ^ 131.1*^ 126.8*^ 122.0 ^ 
(9.38 ± 0.25) ± 4.7 ± 3.7 ±5.2 ± 7.3 ± 6.2 
1,25-(0H)2D3 
25 ug 106.0 
* 
109.3 105.8 104.5 103.3 
(8.58 ± 0.13) ± 2.4 ± 2.0 ± 2.2 ± 1.1 ± 1.1 
100 ug 
* 
111.9 
ft 
115.8 
* 
111 .4 
* 
109.2 107.7 
(9.01 ± 0.03) ± 1.0 ± 1.4 ± 0.9 + 0.9 ± 1.0 
400 ug 
* 
122.3 
* 
119.4 111.4 110.3 105.5 
(9.50 ± 0.26) ± 3.1 ± 4.2 ± 7.0 ± 4.5 ± 3.1 
^Values in parentheses are the prntreatment baseline concentration of 
calcium In mg/100 ml. Pretreatment data are reported as the mean ± SEM. ND = 
Not determined. Significantly different (P S 0.05) from control (ethanol) 
values. ^Significantly different (P < 0.05) from 1,25-(0H)2D3 values at same 
dose. 
Table 2. Plasma phosphorus concentration during the 5 posttreatment periods 
expressed as a percentage of pretreatment phosphorus concentration 
% of Pretreatment Level^ 
Period 1 Period 2 Period 3 Period 4 Period 5 
Treatment (Days 1&2) (Days 3&4) (Days 5&6) (Days 7&8) (Day 9) 
Ethanol 
Control 109.3 
(5.83 ± 0.14) ± 5.2 
100.4 
± 9.2 
88.9 
± 9.1 
100.0 
± 5.5 
105.1 
± 1.5 
24-F-1,25-(0H) 2 D 3  
25 yg 115.7 
(5.65 ± 0.21) ± 8.7 
117.4 
± 5.2 
111.6 
± 7.5 
123.1 
± 9.8 
ND 
100 pg 110.2 
(5.62 ± 0.45) t 9.7 
134.0 
±11.4 
123.8 
± 4.9 
116.0 
±10.7 
ND 
400 pg 140.2 
(5.82 ± 0.69) ± 6.8 
157.5 
±14.3 
155.1 
±16.8 
160.4 
± 1 6 . 4  
150.0 
±29.9 
24,24-F2-l,25-r0H)jD3 
24,24- F 2-l,25-(0H)2D3 
25 yg 117.2 116.3 
* 
116.4 
A 
126.2 ND 
(7.12 ± 0.26) ± 2.2 ± 5.8 ± 8.0 + 2.3 
100 yg 136.5*^ 
* 
]31.6 135.2 
* 
133.8 136.7 
(6.42 ± 0.33) ± 2.1 ±10.6 ±15.3 ± 9.5 ±10.2 
400 yg 144.9 
* 
153.5 145.6* 
* 
134.7 150.1 
(5.37 ± 0.68) ±11.7 ±23.6 ± 9.7 ±21.8 ±22.7 
1,25-(OH)2D3 
25 yg 105.3 107.9 112.0 116.3 109.7 
(6.24 ± 0.52) ± 3.4 ± 9.2 ± 5.1 ± 9.3 ± 6.4 
100 yg 116.0 128.2 
* 
133.7 
* 
139.1 129.3 
(6.45 ± 0.23) ± 4.8 ± 6.7 ± 4.0 ± 6.1 ±13.8 
400 yg 142.7 129.2 126.7 118.9 131.4 
(6.21 ± 0.58) ±17.5 ±11.7 ±12.4 ±10.3 ± 7.4 
^Values in parentheses are the protreatment baseline phosphorus 
concentrations in mg/100 ml. Pretreatment data are reported as the mean ± SEM. 
ND = Not determined. Significantly different (P £ 0.05) from control 
(ethanol) values. ^Significantly different (P è 0.05) from 1,25-(0H)2D3 
values at same dose. 
Table 3. Urinary hydroxyproline excretion rate during the 5 posttreatment 
period expressed as a percentage of pretreatment urinary hydroxy-
proline excretion rate 
% of Pretreatment Level^ 
Period 1 Period 2 Period 3 Period 4 Period 5 
Treatment (Days 1&2) (Days 3&4) (Days 5&6) (Days 7&8) (Day 9) 
Ethanol 
Control 90.7 97.3 119.7 113.1 332.7 
(11.3 ± 1.2) ±13.5 ±14.1 ± 9.8 ± 4.3 ±14.8 
24-F-l,25-(OH) 2D3 
25 ug 136.2* 109.3 113.5 94.1 ND 
(13.3 ± 2.8) ± 7.4 ±16.2 ± 1.8 ±19.8 
100 pg 154.8 136.0 132.5 138.0 ND 
(13.2 ± 3.1) ±38.5 ±20.3 ±11.3 ±16.6 
400 ug 104.2 91.7 
* 
68.3 60.8 ^ 45.5* 
(17.6 ± 2.3) ± 4.5 ±4.7 ± 6.5 ± 3.4 ±24.9 
2/ i ,24-F2-1 ,25-(0H)2D3 
24.24-F2-1.25-(0H)2D3 
25ug 
(15.8  ± 1 ,3)  
100 ug 
(12.9  ± 0 .6)  
400 ug 
(16 .0  ±  0 .2 )  
1,25-(0H)2D3 
25 ug 
(19.3  ± 3 .0)  
113.6  
± 8 .7  
114.9  
±17.2  
110.0 
± 8 .5  
106.3  
± 5 .7  
88 .1  
± 9.3 
87.5 
±16.1 
78.5 
±  8 . 8  
107.5 
± 4.6 
84.5 
±11.7 
78.2 
±21.5 
70.6" 
± 7.6 
95.2  
± 1 .7  
79.4  
±  8 . 0  
6 8 . 6  
± 4 .0  
67.1  
±  6 . 1  
99.9 
±11.5 
ND 
55.7  
± 7 .5  
73.1  
± 8 .9  
98.5 
± 9.9 
100 ug 
(14.6  ± 1 .2)  
400 ug 
(15.4  ± 3 .4)  
138.2  
± 9 .1  
105.0  
±18.9  
102.0 
± 1.9 
87.1 
±18.5 
99.3 
± 5.7 
i 
75.6 
±12.0 
89.6  
±13.0  
i 
91.6  
±10.3  
100.9 
± 9.3 
ND 
^Values in parentheses are the pretreatment baseline urinary hydroxypro-
line excretion rates in mg/min. I'retreatmert data are reported as the mean ± 
* 
SEM. ND = Not determined. Significantly different (P Ê 0.05) from control 
(ethanol) values. ^Significantly different (P s 0.05) from 1,25-(0H)2D3 
values at same dose. 
Table 4. Glomerular filtration rate during tlie 5 posttreatment periods 
expressed as a percentage of pretreatment glomerular filtration rate 
Treatment 
Ethanol 
Period 1 
(Days 1&2) 
% of Pretreatment Level^ 
Period 2 
(Days 3&4) 
Period 3 
(Days 5&6) 
Period 4 Period 5 
(Days 7&8) (Day 9) 
Control 91.7 
(922 ± 108) ±9.1 
24-F-l,25-(0H)zD3 
25 ug 113.9 
(651 ± 136) ± 7.5 
100 yg 127.2 
(693 ± 96) ±14.2 
89.5 
±10.8 
86.4 
± 0.6 
109.1 
±23.6 
106.8 
± 6.1 
93.5 
± 1.7 
114.2 
± 2 0 . 6  
103.5 
± 4.1 
84.6 
± 4.8 
123.4 
±24.6 
101.4 
± 7.0 
ND 
ND 
400 t ig  
/OSS + 
87.4  
4- 7 q 
81.9  
+ 7 
68.4 
+ 
64.2  
± 2 . 3  
61.5  
± 1 .3  
400 ug 
(955 ± 125) 
87.4 
± 7.5 
Hi.y 
± 7.6 
OO . H 
±  2 . 6  ± 2.3 ± 1.3 
24,24-F2-l,25-(0H)2D3 
25 pg 
(1091 ± 91) 
100 Ug 
(794 ± 129) 
400 ijg 
(899 ± 83) 
1.25-(0H)2D3 
25 wg 
(819 ± 58) 
100 ug 
(758 ± 13) 
400 iig 
(916 ± 65) 
8 9 . 6  
± 4.1 
107.5 
±14.9 
84.2 
± 3.5 
105.6 
± 3.9 
110.9 
± 6.3 
104.6 
±28.3 
94.8 
± 4.0 
92.4 
±3.1 
69.3 
± 4.8 
102.9 
±  1 . 2  
99.1 
±  0 . 8  
83.9 
± 9.7 
90.4 
± 7.1 
8 8 . 6  
±5.1 
d 
6 2 . 6  
± 4.6 
105.7 
±12.7 
94.4 
± 4.1 
69.7' 
±12.5 
88.9 
±  8 . 6  
67.8^ 
± 2.7 
63.8^ 
±10.3 
97.2 
± 3.4 
89.4 
±  6 . 6  
96.4 
±12.9 
MD 
60.5 
± 7.1 
57.9/ 
± 9.3 
* 
103.0 
±  2 . 6  
97.7 
± 5.8 
ND 
^Vnlues In parentheses are the pretreatment baseline glomerular filtra­
tion rate in ml/min. Pretreatment data are reported as the mean.± SEH. ND = 
* 
Not determined. Significantly different (P < 0.05) from control (ethanol) 
values. 
Table 5. Urinary calcium excretion rate during the 5 posttreatment periods 
expressed as a percentage of pretreatment urinary calcium excretion 
rate 
% of Pretreatment Level^ 
Period 1 Period 2 Period 3 Period 4 Period 5 
Treatment (Days 1&2) (Days 3&4) (Days 5&6) (Days 7&8) (Day 9) 
Ethanol 
Control 111.0 
(0.87 ± 0.43) ±23.0 
132.2 
±44.6 
368.0 
± 2 6 . 6  
129.5 
± 5.5 
84.0 
±19,7 
24-F-1,25-(0H)2D3 
25 lig 137.6 
(0.52 ± 0.22) ±76.7 
182.3 
±72.3 
315.9 
±42.8 
260.4 
±38.7 
ND 
100 ug 977.0 
(0.99 ± 0.52) ±800.6 
546.3 
±291.8 
817.8 
±509.2 
685.4 
±389.5 
ND 
400 lip 
(1.96 ± 1.40) 
232.7 
+13 7.0 
214.2 
±118.3 
250.0 
±146.2 
279.7 
±357.8 
106 .0  
±34.5 
400 yg t ^ j.-r « A. 
(1.96 ± 1.40) ±137.0 ±118.3 ±146.2 ±157.8 ±34.5 
24,24- F 2-1,25-(0H)2D3 
25 ug 281.0 360.8 259.0 190.5 ND 
(0.26 ± 0.03) ±47.3 ±91.2 ±37.0 ±20.4 
100 yg 310.0 194.6 166.7 163.0 86.0 
(0.92 ± 0.29) ±208.6 ±155.5 ±79.2 ±22.5 ±30.6 
400 yg 180.1 68.5 64.6 148.0 65.0 
(1.22 ± 0.17) ±38.7 ±22.9 ± 4.6 ±63.6 ±14.5 
l,25-(OH)2D3 
25 yg 237.7 735.8 353.0 166.0 198.0 
(0.37 ± 0.28) ±82.1 ±429.5 ±98.6 ±33.5 ±30.6 
100 yg 582.0 
* 
872.6 811.5 602.0 690.0 
(0.30 ± 0.08) ±193.0 ±280.6 ±350.3 ±260.7 ±292.5 
400 yg 123.1 97.7 61.0 67.6 ND 
(0.71 ± 0.28) ±52.9 ±32.6 ±10.5 ±13.2 
^Values In parentheses are the pretrentnient baseline urinary calcium 
excretion rates in g/day. Data are reported as the mean ± SEM. ND = Not 
determined. Significantly different (P S 0.05) from control (ethanol) 
values. 
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SECTION II. 
USE OF 2A-F-1,25-DIHYDR0XYVITAMIN Dg TO PREVENT PARTURIENT 
PARESIS (MILK FEVER) IN DAIRY COWS 
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INTRODUCTION 
Parturient paresis (milk fever) continues to be a major source of 
loss in terms of productivity, increased predisposition to secondary 
disease problems, treatment costs, and cow deaths. Many measures to 
prevent parturient paresis have been suggested. Among these are 
adjustment of calcium content of prepartal diets (Hove, 1986; Jorgen-
sen, 1974) and the use of vitamin D and its derivatives (Barlet, 1977; 
Cast a^., 1979; Hibbs and Pounden, 1955; Hove and Kristiansen, 
1982; Sachs £t al., 1977). 
The major problem with the use of 1,25-dihydroxyvitamin Dg 
[1,25-(0H)2D3] and la-hydroxyvitamin D3 (la-OHDg) is in the timing of 
the administration of these sterols relative to parturition. When 
1,25-(0H)2D3 or la-OHDg are administered between 1 and 3 days before 
calving, they are effective in preventing parturient paresis (Hoffsis 
e_t al., 1978; Sachs e^ al., 1977). Outside this time period, they are 
less effective. Prevention of parturient paresis would be more 
practical if the period of efficacy of the vitamin D sterols could be 
extended so as to circumvent difficulties in predicting the actual 
time of parturition. 
The duration of action of 1,25-(0H)2D3 can be extended by fluori­
dation of the 24th carbon which blocks 24-hydroxylation of the side-
chain of 1,25-(0H)2D3, a major degradative pathway (Okamoto et al., 
1983). We have found that 24-F-l,25-(0H)2D3 is about 1.5 times as 
potent and acts over a longer period than does 1,25-(0H)2D3 in 
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nonpregnant cows (Goff et al., 1986), Our objective was to develop a 
protocol for the prevention of parturient paresis in dairy cows using . 
24-F-l,25-(OH)2D3 administration. 
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MATERIALS AND METHODS 
Twenty-nine periparturient Jersey cows, weighing between 400 and 
450 kg, were selected from the National Animal Disease Center research 
herd. All cows had at least three previous lactations and all had 
histories of parturient paresis at a previous calving. Six weeks 
prepartum, cows were fed alfalfa hay ad libitum and 4.5 kg concentrate 
feed, which supplied approximately 110 g calcium and 33 g phosphorus 
daily. Approximately 2 weeks prepartum, the cows received an addi­
tional 7.3 kg of concentrate daily so that their diet supplied about 
150 g calcium and 76.8 g phosphorus per day in the last days of gesta­
tion and for the first 2 weeks of lactation. 
Cows were randomly allocated to either the control group or one 
of the two treatment groups. Five days before the expected day of 
parturition, experimental cows were treated with either 100 ug (n = 7) 
or 150 yg (n = 10) of 24-F-l,25-(OH)2D3 intramuscularly (IM). Cows 
that did not calve within 7 days received a second dose of 24-F-l,25-
(0H)2D3. One cow in each experimental group did not calf within 7 
days of the second injection and was given a third injection of the 
experimental drug. Twelve control cows were left untreated. 
The 24-F-l,25-(OH)2D3 used in these trials was the gift of M. R. 
Uskokovic (Hoffmann-La Roche, Inc., Nutley, NJ). The concentration of 
24-F-l,25- (OHÏgDg was determined using UV spectroscopy (^£64 ~ 18,200 
m and then dissolved in Neobee oil at a concentration of either 100 
or 150 yg/ml. 
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Daily plasma samples were obtained from all cows between the 10th 
day prior to parturition and the 14th day postpartum. Around the time 
of parturition, sampling was more frequent. 
Concentrations of calcium and magnesium in plasma were determined 
by atomic absorption spectrophotometry (Perkin-Elmer Corp., 1965). 
Plasma inorganic phosphorus (Fiske and Subbarrow, 1925), hydroxypro-
line (Bannister and Burns, 1970), and creatinine (Chasson et al., 
1961) were determined by colorimetric methods adapted to an Auto-
Technicon Analyzer. Plasma parathyroid hormone (PTH) concentrations 
were determined by radioimmunoassay using an antibody directed against 
middle and N-terminal portions of the PTH molecule (Arnaud ££ al., 
1971). The method of Reinhardt et £l. (1984) was modified to allow 
determination of both 1,25-(0H)2D3 and 24-F-l,25-(0H)2D3 in plasma. 
24-F-l,25-Dihydroxyvltamin D3 and 1,25-(0H)2D3 comigrated on C18 
Sep-Pak Silica columns. Separation was achieved by subjecting the 
dihydroxyvitamin D metabolite fraction from the initial CIS Sep-Pak 
column to high-performance liquid chromatography (HPLC) on a Zorbax 
Sil column (0.45 x 25 cm, Dupont) developed in 3:97 isopropanol/methy-
lene chloride. Once separated, concentrations of both sterols were 
determined by using a radioreceptor assay (Reinhardt et. » 1984) . 
Recovery estimates for 1,25-(0H)2D3 were used to estimate recovery of 
24-F-1,25-(0H ) 2 D 3 .  
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RESULTS 
A summary of animal allocation and clinical results within each 
experimental group is presented in Table 1. Ninety-two percent of the 
control cows developed clinical parturient paresis. Most of these 
cases occurred between parturition (day 0) and 2 days postpartum. One 
cow became paretic 12 days after calving. Three of the 11 paretic 
control cows suffered relapses of parturient paresis requiring further 
treatment with intravenous calcium solution. 
Treatment of cows with either 100 pg or 150 yg of 24-F-l,25-
(0H)2D3 prior to parturition reduced the incidence of parturient 
paresis to 43% and 20%, respectively. No relapses were seen in the 
24-F-l,25-(0H)2D3-treated cows that developed parturient paresis. 
Plasma calcium concentrations of control and 24-F-l,25-(OH)2D3-
treated cows are presented In Figure 1. Data derived from the control 
cow that did not develop parturient paresis are Included in the data 
for the control cows. The degree of hypocalcemia exhibited by paretic 
24-F-l,25-(OH)2D3-treated cows is similar to that of control cows with 
paresis. Cows treated with 24-F-l,25-(OH)2D3 that did not develop 
paresis exhibited mild hypocalcemia when compared to control- or 
treated cows that developed paresis. 
Control cows exhibited a fivefold increase in plasma 1,25-(0H)2D3 
concentration around the time of parturition. Plasma concentrations 
of 1,25-(0H)2D3 were only slightly elevated in both paretic and 
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nonparetic 24-F-l,25-(0H)2D3-treated cows (Figure 2). Plasma concen­
trations of 1,25-(0H)2D3 was inversely proportional to plasma calcium 
concentration in control cows, but not in paretic 24-F-l,25-(0H)2D3-
treated cows. 
Plasma concentrations of iPTH were similar in control and paretic 
24-F-l,25-(0H)2D3-treated cows (Figure 3), exhibiting a threefold 
increase around the time of parturition. Plasma iPTH was increased 
only slightly in nonparetic 24-F-l,25-(OH)2D3-treated cows. Plasma 
concentration of iPTH was inversely proportional to plasma calcium 
concentration in all cows. 
Plasma hydroxyproline concentrations were low in all cows prior 
to parturition and rose significantly in all caws after parturition. 
Plasma hydroxyproline and creatinine concentrations in control cows 
and 24-F-l,25-(OH)2D3-treated cows were not significantly different 
before or after parturition. 
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DISCUSSION 
These studies demonstrate that 24-F-l,25-(OH)2D3 can prevent 
parturient paresis in susceptible dairy cows. The greatest protection 
against parturient paresis was afforded by 150-vig doses of 24-F-l,25-
(OH^zDg. Cows that calved between one day and 7 days after the first 
injection were protected from parturient paresis. A second injection, 
7 days after the first, prevented parturient paresis for an additional 
7 days in all but one cow. When 24-F-l,25-(OH)2D3 was administered in 
100-Mg doses, the period of protection was less than 7 days (Table 1). 
We did not detect any undesirable effects of repeated 150-vig doses of 
24-F-l,25-(0H)2D3 in this study. Plasma creatinine concentrations 
were normal and did not change significantly in treated cows, 
indicating that renal function was not affected. A larger dose of 
24-F-l,25-(0H)2D3 might be more effective in preventing parturient 
paresis; however, the possibility of toxicity would be greatly 
increased as well. This conclusion is based on studies in nonpregnant 
cows in which 400-tig doses of 24-F-l,25-(OH) 203 caused significant 
reductions in renal glomerular filtration rate (Goff al., 1986). 
Hydroxyproline is an amino acid unique to collagen. Plasma levels of 
hydroxyproline can be useful indices of bone resorption activity (Dull 
and Henneman, 1963). However, because hydroxyproline of uterine 
origin also enters the blood after calving, the usefulness of 
hydroxyproline determinations is limited to the prepartal period. We 
did not observe any significant differences in prepartal plasma 
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hydroxyproline concentrations between control cows and those 24-F-
l,25-(0H)2D3-treated cows that had been injected more than 6 days 
prior to calving (data not shown). In controlled studies on nonpreg­
nant cows, the administration of 1,25-(0H)2D3, 24-F-l,25-(OH)2D3, 
24,24-F2-1,25-(0H)2D3, and la-0HD3 either had no effect on or inhibited 
bone resorption (Bar al., 1985; Goff al., 1986). Our results 
confirm that vitamin D sterols do not stimulate bone resorption in 
dairy cows prior to parturition. The hypercalcemic activity of 
vitamin D sterols in ruminants resides primarily in their ability to 
enhance intestinal calcium absorption (Braithwaite, 1978; Hove, 1984). 
Despite nearly identical degrees of hypocalcemia, the 24-F-l,25-
(OH)2D3-treated cows that developed parturient paresis had much lower 
plasma 1,25-(0H)2D3 concentrations around the time of parturition than 
did control cows. The use of 24-F-l,25-(OH)2D3 inhibited the expected 
increase in plasma 1,25-(0H)2D3 as a homeostatic response to hypocal­
cemia. Other vitamin D sterols are known to inhibit endogenous 
production of 1,25-(0H)2D3 in cows (Littledike £t £l., 1986), and 
24-F-l,25-(OH)2D3 probably acts similarly. While vitamin D sterols 
stimulate one calcium homeostatic mechanism (intestinal calcium 
absorption), they may inhibit the cow's natural homeostatic mechanisms 
that respond to hypocalcemia. 
We feel that a 150-ug dose of 24-F-l,25-(0H)283 enhances intesti­
nal calcium absorption over a 7-day period to the extent that the 
calcium demands of initiating lactation can be met solely from dietary 
calcium. When. 24-F-l,25-(OH)2D3 is administered in lOO-yg doses. 
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intestinal calcium absorption is adequately enhanced to meet calcium 
demands for only about 5 days. 
Several groups have reported that vitamin D sterols reduced the 
incidence of parturient paresis occurring around the time of calving, 
but increased the incidence of parturient paresis occurring more than 
4 days postpartum (Hove, 1986; Littledike and Horst, 1982). Prolonged 
inhibition of the cow's natural homeostatic mechanisms were believed 
to have contributed to the development of hypocalcemia in these cases. 
In this study, only one 24-F-l,25-(0H)2D3-treated cow developed 
parturient paresis more than 4 days postpartum. However, climatic 
conditions were a major factor in this case. Ten days after this cow 
calved, Iowa received a severe snowstorm which prevented normal 
feeding and milking procedures that afternoon and the following 
morning. Shortly after being milked on the 11th day postpartum, the 
cow developed clinical parturient paresis. A possible significant 
difference between this study and earlier studies in which delayed 
cases of parturient paresis were prominent was the level of calcium 
supplied in the postpartum diet. The high calcium diet used in this 
study may have allowed the cows to better utilize the remaining 
calcium transport mechanisms as exogenous 24-F-l,25-(0H)2D3 action on 
the intestine declined. The vitamin D sterol-treated cow may have a 
greater requirement for dietary calcium after parturition than does 
the untreated cow. Endogenous 1,25-(0H)2D production is inhibited by 
these compounds, and it seems likely that hypercalcemia induced by 
these compounds during the peripartal period might leave bone calcium 
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resorption mechanisms inactivated. Thus, plasma calcium concentration 
in the vitamin D-treated cow may be dependent on just one branch of 
the calcium homeostatic mechanism-intestinal calcium absorption. We 
are currently investigating the efficacy of 24-F-l,25-(OH)2D3 in cows 
fed diets containing less calcium. 
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Figure 1. Plasma calcium concentration around the time of•parturition 
in control cows and cows treated with 24-F-l,25-(OH)2D3• 
Eleven of the 12 control cows and those 24-F-l,25-(OH)2D3-
treated cows that developed paresis were treated with 
intravenous calcium at their calcium nadir 
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Figure 2. Plasma 1,25-(OH)2D concentration around the time of par­
turition in control cows and cows treated with 24-F-
1,25-(0H)2D3 
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Figure 3. Plasma immunoreactive PTH concentration around the time of 
parturition in control cows and cows treated with 24-F-
1.25-(0H)2D3 
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Table 1. Summary of animal allocation and clinical results within 
each experimental group 
Interval from 
Control Calcium minimum Day of No. of treatment to 
cow observed occurrence relapses parturition 
Control 
1 4.9 +2 No-PP N/A 
2 3.8 +1 0 N/A 
3 4.5 +1 0 N/A 
4 3.7 +1.5 0 N/A 
5 3.7 +2 1 N/A 
6 3.3 +0.5 0 N/A 
7 4.7 0 0 N/A 
8 4.3 0 2 N/A 
9 3.5 +0.5 0 N/A 
10 4.0 0 0 N/A 
11 3.5 +1 1 N/A 
12 3.8 +12 0 N/A 
100 yg 24-F-1,25-(0H)2D3 
1 6.0 +0.5 No-PP 3 
2 5.5 +1 No-PP 7 
3 6.0 +2 No-PP 3 
4 7.6 +2 No-PP 3 
5 5.0 -0.5 0 1 
6 4.3 +0.5 0 7 
7 2.7 +1 0 7 
150 yg 24-F-1,25-(0H) 2 D 3  
1 7.7 +4 No-PP 6* 
2 6.2 +9 No-PP 1 
3 5.6 +3 No-PP 7 
4 6.1 +2 No-PP 6 * 
5 7.2 0 No-PP 0.5** 
6 5.8 0 No-PP 0*3* 
7 6.1 +0.5 No-PP 0 
8 6.2 +7 No-PP 2 
9 4.5 +0.5 0 1 * 
10 4.1 +11 0 0.5 
^No-PP = Did not develop clinical parturient paresis. N/A = Not 
* ** 
applicable. After 2nd dose of 24-F-l,25-(0H)2D3. After 3rd dose 
of 24-F-l,25-(OH)2D3. Calved within 4 hours after 2nd dose. 
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SECTION III. 
EFFECT OF SYNTHETIC BOVINE PARATHYROID HORMONE IN DAIRY COWS: 
PREVENTION OF PARTURIENT PARESIS (MILK FEVER) 
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INTRODUCTION 
Parturient paresis (milk fever) is primarily a hypocalcemia 
disorder of dairy cows associated with the onset of lactation. Though 
the predisposing factors, clinical signs, and clinical pathology of 
the syndrome have been well characterized, the basic cellular and 
biochemical mechanisms that cause parturient paresis are not well 
understood. In 1925, Dryerre and Greig suggested that the hypocal­
cemia might be the result of Insufficient parathyroid hormone (PTH) 
secretion. However, subsequent workers using radloimmunological and 
histologic techniques concluded that PTH secretion in response to 
hypocalcemia in cows developing parturient paresis is equal to or 
greater than that of nonparetlc cows (Capen and Young, 1967; Horst £t 
al., 1978; Mayer et al., 1969). Several research groups (Hibbs "et 
al., 1947; Jackson et al., 1962; Little and Mattick, 1933) injected 
cows with crude extracts of PTH and found that older prepartal cows 
were less responsive to PTH than young cows and that PTH administra­
tion did not prevent parturient paresis. Martig and Mayer (1972) 
observed that the prepartum cow responded to exogenous PTH, although 
this response was blunted when compared with the postpartal response. 
These findings lead to the current theory that the responsiveness of 
the target tissues to PTH stimulation may be deficient or delayed in 
the periparturient cow. 
Since these earlier reports, the physiologic function of PTH and 
its interactions with the vitamin D endocrine system have been 
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discovered. PTH is secreted in response to hypocalcemia and in turn 
stimulates renal conservation of calcium and release of calcium from 
bone stores. Also, by activating renal enzymes, PTH plays an intimate 
role in the production of 1,25-dihydroxyvitamin D [1,25-(0H)2D], which 
increases intestinal calcium absorption (DeLuca, 1979). 
Parturient paresis can be prevented by feeding cows very low 
calcium diets (< 20 g/d) for 2 wk prior to parturition (Goings et al., 
1974). This stimulates endogenous PTH secretion which in turn 
increases renal production of 1,25-(0H)2D. Together, PTH and 
1,25-(0H)2D stimulate mechanisms that resorb bone calcium and increase 
the active transport of calcium across the intestinal epithelium 
(Green et al., 1981; Kichura et al., 1982). The effectiveness of the 
low calcium diet in preventing parturient paresis suggested that 
calcium homeostatic mechanisms had to be primed during the prepartal 
period if they were to be fully responsive to the calcium demand 
associated with the onset of lactation. 
The purpose of the present study was to determine if exogenous 
PTH administration could also prime the calcium homeostatic mechanisms 
and thus prevent parturient paresis. 
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MATERIALS AND METHODS 
Pregnant Cow Experiment 
Nine Jersey cows in the last trimester of pregnancy, weighing 
between 380 and 440 kg, were kept in individual stanchions and fed a 
complete pelleted diet that supplied 10.1 MCal Net Energy, 0.83 kg 
protein, 68 g calcium, and 35 g phosphorus daily. 
Teflon catheters were placed in one external jugular vein under 
local anesthesia 12 to 20 h before the start of the experiment. At 
the same time, a noninvasive urine collection device was sutured to 
the cow's perineal region under standing epidural anesthesia. Urine 
was collected in polyurethane bottles to which 100 ml glacial acetic 
acid had been added as a preservative before the start of each 
collection period. 
All cows were infused intravenously with 0.9% saline containing 
0.2% bovine serum albumin (BSA) without PTH for 32 to 48 h and then 
infused with 0.9% saline containing BSA and PTH in accord with one of 
three treatment regimens. Bovine serum albumin was added to infusion 
solutions to minimize loss of PTH activity as a result of nonspecific 
binding of protein to glass and tubing. Highly-purified BSA 
(essentially fatty acid and globulin-free, Sigma Chemical Co., St. 
Louis, MO) was used to minimize introduction of endotoxins into 
infusion solutions. Crude synthetic N-terminal 1-34 fragment of 
bovine PTH (lot #007242, Peninsula Laboratories, Inc., San Carlos, CA) 
containing 767 units/mg (Nissenson al., 1981) was given to four 
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cows at a rate of 146 yg/h for 48 h (3.5 mg/d), to three cows at a 
rate of 146 wg/h for 96 h (3.5 mg/d), and to two cows at a rate of 73 
Ug/h for 96' h (1.7 mg/d). The PTH solution was prepared fresh every 
24 h and contained 1 to 2 ml of a stock solution of PTH in 0.01 M 
acetic acid diluted in sterile 0.9% saline containing 0.2% BSA. 
Infusate solutions were maintained in ice water and delivered at a 
rate of 0.5 ml/min by means of an external infusion pump (Rainin 
Instrument Co., Inc., Emeryville, CA). 
Blood samples were taken by subcutaneous abdominal (milk vein) 
venipuncture at regular intervals throughout the experiment. Plasma 
was separated immediately by centrifugation and stored at -15°C until 
analyzed. Urine was collected over 8- or 12-h periods throughout the 
experiment. Volumes were recorded, and a representative sample was 
frozen for analysis. 
Periparturient Cow Experiment 
Eight periparturient Jersey cows, weighing between 400 and 450 
kg, were selected from the National Animal Disease Center research 
herd. All cows had at least three previous lactations and all had 
histories of parturient paresis at a previous calving. Six-wk 
prepartal cows were fed alfalfa hay ad libitum and 4.5 kg concentrate 
feed that supplied approximately 110 g calcium and 33 g phosphorus 
daily. Approximately 2 wk prepartum, the cows received an additional 
7.3 kg of concentrate daily so that their diet contained approximately 
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150 g calcium and 78 g phosphorus per d in the last days of gestation 
and for the first 2 wk of lactation. 
Approximately 3 wk prepartum, a small programmable titanium pump 
(Medtronics Inc., Minneapolis, MN) was implanted under the skin of 
four of the cows. In two of the cows, the pump was located in the 
paralumbar fossa and was connected to a teflon catheter placed in the 
circumflex iliac vein. The pump was implanted in the neck in two 
other cows and connected to a catheter in the jugular vein. All 
surgery was performed under local anesthesia (lidocaine). Ace-proma-
zine (20 mg. Fort Dodge Laboratories, Fort Dodge, lA) was used as a 
sedative. High epidural spinal block was used in the case of the cows 
with the catheterized circumflex iliac vein. The pump had a 20-ml 
reservoir that could be refilled by injection through the skin into a 
silicone port on the pump. Four other cows (that did not undergo 
surgery) served as controls. 
All four treated cows received saline at a rate of 8.7 ml/d from 
the time of surgery until the PTH solution was administered. PTH 
solutions were made up every 48 h to refill the pump by dilution of 
stock PTH (in 0.01 M acetic acid) with 0.1% bovine serum albumin 
saline. 
Cow #1 received PTH at a rate of 217 yg/h from 60 h prepartum to 
12 h prepartum, at which time the infusion rate was decreased to 104 
yg/h and continued until 55 h postpartum. 
Cow #2 received PTH at a rate of 104 yg/h from 116 h prepartum 
until 55 h postpartum. 
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Cow #3 received PTH at a rate of 58 pg/h from 16 h prepartum to 5 
h postpartum, at which time the rate was increased to 146 yg/h and 
continued until 48 h postpartum. At that time, the infusion rate was 
returned to 58 pg/h for another 48 h. 
Cow #4 received PTH at a rate of 104 yg/h beginning 10 h pre­
partum and continuing until 96 h postpartum. 
Plasma samples were obtained by jugular venipuncture on the side 
opposite the pump daily prior to parturition and for 14 d postpartum. 
Around the time of parturition sampling was more frequent. 
Parameters Monitored 
Concentrations of calcium and magnesium in plasma and urine were 
determined by atomic absorption spectrophotometry (Perkin-Elmer 
Corporation, 1965). Plasma and urine inorganic phosphorus concentra­
tions were determined colorimetrically (Fiske and Subbarrow, 1925). 
Concentrations of hydroxyproline in plasma and urine were 
monitored as an estimate of bone resorption activity (Dull and 
Henneman, 1963). Free plasma hydroxyproline and total urinary 
hydroxyproline were determined colorimetrically (Bannister and Burns, 
1970; Hosley e^ al., 1970). Renal function was assessed by monitoring 
urine specific gravity and renal glomerular filtration rate. 
Glomerular filtration rate was estimated by determining endogenous 
creatinine clearance rate. Plasma and urine creatinine concentrations 
were determined colorimetrically on an AutoTechnicon Analyzer (Chasson 
e^ £l., 1961). Plasma concentrations of 1,25-(OH)2D were determined 
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as described by Reinhardt e£ £l. (1984). Plasma PTH concentrations 
were determined by radioimmunoassay using an antibody directed against 
middle and N-terminal portions of the PTH molecule (Arnaud ^  aJ., 
1971). 
The differences between the observed values at each time point 
during the infusion and the values observed during the control period 
prior to infusion were determined for each parameter measured. 
Student's paired ^  test was used to test the hypothesis that the mean 
difference was equal to zero. 
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RESULTS 
Pregnant Cow Experiment 
Parathyroid hormone infusion at 146 pg/h for 48 h resulted in 
significant changes in plasma calcium, 1,25-(0H)2D, and magnesium 
concentrations (Table 1, Figure 1). Plasma calcium was increased 32% 
(P < 0.05), while plasma phosphorus was decreased 30% (P < 0.05) after 
48 h of infusion. Plasma concentration of magnesium increased more 
rapidly than did calcium concentration and also decreased more rapidly 
once PTH infusion ended. No significant changes were seen in plasma 
hydroxyproline or plasma PTH concentrations. 
Plasma 1,25-(OH)2D,concentrations increased within 8 h (Figure 2) 
and were maximal between 24 and 32 h after the start of infusion, at 
which time they were 4 to 5 times pretreatment levels. Although 
plasma 1,25-(OH)2D concentrations decreased as infusion of PTH 
continued, they remained above preinfusion levels. Within 48 h after 
PTH infusion ended, plasma 1,25-(0H)2D concentrations were equivalent 
to pretreatment concentrations. 
Parathyroid hormone caused a rapid decrease in urinary excretion 
of calcium and magnesium within 24 h of the sta.rt of infusion. Once 
PTH infusion was stopped, urinary excretion of calcium increased to 
nearly four times the rate during the control period. In contrast, 
there was no excessive loss of magnesium via the urine when PTH was 
withdrawn. Urinary phosphorus excretion was significantly increased 
(P < 0.05) by PTH infusion and remained high for 48 h after PTH was 
89 
withdrawn. Urinary excretion of hydroxyproline was not increased by 
48 h of infusion of 146 yg PTH/h. 
The effects of infusion of PTH for 96 h were similar to those 
seen when PTH was administered for only 48 h (Table 2, Figure 1). 
Plasma calcium concentration increased linearly as long as PTH 
infusion was maintained (Figure 1). Plasma concentration of 
1,25-(OH)2D was greatly elevated by PTH infusion initially. However, 
as PTH infusion continued, the mean plasma concentration of 1,25-
(OHOaD decreased so that by the end of the infusion period plasma 
1,25-(0H)2D concentration was only about two times the pretreatment 
level (Figure 2). Plasma concentration of hydroxyproline was signif­
icantly increased after 72 h of PTH infusion (P < 0.05) and continued 
to increase until PTH infusion ceased. Plasma hydroxyproline concen­
tration returned to pretreatment level within 24 h after PTH with­
drawal. 
Urinary losses of calcium, phosphorus, and magnesium paralleled 
those changes seen during the 48-h infusion experiment (data not 
shown). An important difference was that urinary excretion of 
hydroxyproline was significantly increased (P < 0.05) between 48 and 
96 h of PTH infusion (Figure 3). Urinary hydroxyproline excretion 
rapidly returned to pretreatment levels when infusion ceased. 
Between 72 and 96 h of the infusion period, feed intake was 
greatly reduced. This corresponds to the time of maximal hypercal­
cemia. Appetite returned to normal about 48 h after PTH infusion 
ceased. 
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When 73 ug PTH/h was administered for 96 h, there were no 
significant changes in plasma concentrations of calcium, hydroxypro-
line, 1,25-(0H)2D, magnesium, phosphorus, or PTH (Table 2). There 
were no significant changes in the urinary excretion rates for 
calcium, magnesium, or hydroxyproline. However, 73 yg PTH/h did 
increase urinary phosphorus excretion (P < 0.05) during the infusion 
period (data not shown). 
Plasma concentrations of immunoreactive PTH (iPTH) were not 
significantly increased during any of the PTH infusions, even at the 
146 yg PTH/h dose (Table 1). Plasma PTH levels did not decrease 
significantly once PTH Infusion ceased. 
Parathyroid hormone treatment did not result in any significant 
changes in renal glomerular filtration rate during the course of these 
trials (data not shown). Urine specific gravity was lower at the end 
of the 146 yg/h infusion periods than before infusion, but the cows 
did not exhibit any other indications that renal function was 
impaired. 
Periparturient Cow Experiment 
All four of the cows that did not receive PTH infusions developed 
severe hypocalcemia, became recumbent with parturient paresis (Figure 
4), and required treatment with an Intravenous solution containing 
calcium, magnesium, and phosphorus (Norcalciphos, Norden Labs., 
Lincoln, NE). One control cow suffered a relapse, requiring a second 
treatment. 
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The two cows that received PTH intravenously for at least 60 h 
before parturition (Nos. 1 and 2, Figure 5) did not become hypocal-
cemic at any time during the experiment. Both cows were actually 
hypercalcemic at parturition in contrast to the control cows. The two 
cows that began receiving PTH intravenously less than 24 h prior to 
parturition (Nos. 3 and 4, Figure 6) were hypocalcemic at parturition 
and shortly after. Cow #3 never exhibited any symptoms of parturient 
paresis, though her plasma calcium was 5.8 mg/100 ml at 18 h 
postpartum. Between 18 and 36 h postpartum, her plasma calcium rose 
rapidly and she became slightly hypercalcemic. Cow #4 exhibited 
several signs of parturient paresis, though she never became 
recumbent. She was dull, inappetant, and exhibited muscle tremors. 
She remained severely hypocalcemic (approximately 4.0 mg/100 ml) 
during the 48 h following parturition. Her plasma calcium then 
increased rapidly until by 96 h postpartum she was slightly 
hypercalcemic, at which time the PTH infusion was ended. None of the 
PTH-treated cows developed any significant hypocalcemia from the time 
PTH infusion was ended until the time sampling ceased (day 14 post­
partum) . 
The control cows exhibited great increases in plasma concentra­
tions of PTH and 1,25-(OH)2D which were inversely proportional to the 
degree of hypocalcemia present (Figure 4). The two PTH-treated cows 
that became hypocalcemic also responded by greatly increasing plasma 
PTH and 1,25-(OH)2D concentrations (Figure 6). The two cows that 
received PTH and did not develop hypocalcemia did not have greatly 
92 
elevated levels of PTH or 1,25-(0H)2D during the infusion period 
(Figure 5). 
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DISCUSSION 
Parathyroid hormone is an important regulator of renal la-hydroxy-
lase and, therefore, synthesis of 1,25-(OH)2D, which is necessary for 
active transport of calcium across the intestinal epithelium. While 
it is clear that PTH can stimulate la-hydroxylase activity under 
hypocalcemic conditions (Aksnes and Aarskog, 1980; Treschel et al., 
1980; Kremer and Goltzman, 1982), the effects of PTH under normocal-
cemic or even slightly hypercalcemic conditions are not clearly 
defined. 
Hove e^ al. (1984) reported that PTH infusion increased plasma 
1,25-(OH)2D concentrations when administered to thyroparathyroidecto-
mized lactating goats that were hypocalcemic, but not if the goats 
were hypercalcemic. This suggested that hypercalcemia may block PTH 
stimulation of renal la-hydroxylase. 
When we administered 146 yg PTH/h to pregnant dairy cows in late 
gestation, a fivefold increase in plasma concentrations of 1,25-(0H)2D 
developed after 32 h of infusion. The concentration of 1,25-(OH)2D 
decreased as the PTH infusion continued. However, even after 2 d of 
hypercalcemic conditions, plasma concentrations of 1,25-(OH)2D re­
mained above pretreatment levels. We conclude that hypercalcemia 
blunts the responsiveness of plasma 1,25-(0H)2D to exogenous PTH, but 
does not eliminate it. In support of this conclusion is the observa­
tion that plasma 1,25-(OH)2D concentrations in humans with primary 
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hyperparathyroidism are often elevated despite hypercalcemia (Broadus 
al., 1980; Gray et al., 1977; Haussier £t al., 1975). 
Parathyroid hormone administration to pregnant cows dramatically 
increased urinary excretion of phosphorus while decreasing urinary 
calcium losses as seen in earlier experiments (Mayer et. » 1966). 
In contrast to PTH effects in humans (Aksnes and Aarskog, 1980), 
phosphaturia is not an immediate response to PTH administration in 
cows. We did not detect significant phosphaturia in the cows until 
after 38 to 48 h of PTH infusion. This also coincides with the time 
of development of hypercalcemia in the cows. Possibly, calcitonin 
secretion in response to the hypercalcemia may be responsible for much 
of the phosphaturia seen (Munson, 1976). PTH decreased urinary 
calcium loss, but the total amount of calcium conserved was actually 
less than 500 mg/d for most cows. 
Plasma hydroxyproline concentration and urinary hydroxyproline 
excretion were increased at 72 and 96 h of PTH infusion at 146 yg/h. 
The 3-day lag time between the start of PTH infusion and the stimula­
tion of significant bone resorption may explain the failure of PTH 
infusion to prevent hypocalcemia in those pregnant cows that calved 
less than 24 h after the start of PTH infusion. If maintained for at 
least 3 d, exogenous PTH can stimulate bone resorption in the pregnant 
cow. 
Infusion of bovine N-terminal 1-34 PTH had obvious physiologic 
effects on the cows; however, we could not detect any increase in 
plasma PTH concentration. Depending on the antlsera used. 
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radioimmunoassay of PTH detects varying amounts of both active and 
inactive fragments of PTH. Bioassays of plasma PTH concentrations in 
man indicate that only about 1% of the radioimmunoassayable PTH is 
biologically active (Nissenson et al., 1981). Therefore, even if PTH 
infusion into cows greatly increased the amount of biologically active 
PTH circulating in plasma, it is unlikely it could be detected by 
radioimmunoassay. Our data suggest that the ability of cows to 
secrete or produce biologically active PTH in the prepartal period may 
not be adequate. Whether this is a defect in the form or amount of 
PTH secreted or in peripheral metabolism necessary for activation of 
PTH Is not known. Characterization of the forms of PTH secreted and 
its peripheral metabolism in the periparturient cow will be crucial to 
establish the fundamental pathogenesis of parturient paresis. 
The management of our experimental herd of Jersey cows results in 
an extremely high incidence of parturient paresis. Of the 28 cows 
that have been subjected to our high-calcium feeding regime, 26 
developed parturient paresis. Prepartal PTH administration to the 
four periparturient cows in this study prevented parturient paresis in 
all four cows and the development of hypocalcemia in two of the cows. 
Parathyroid hormone may be able to prevent parturient paresis because 
it stimulates bone resorption of calcium and enhances intestinal 
absorption of calcium. Although PTH can cause a significant reduction 
in urinary calcium losses, the amount of calcium conserved is not 
likely to contribute significantly to the maintenance of plasma 
calcium in the paresis-prone cow. 
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Vitamin D metabolites have been used to prevent parturient 
paresis (Bar e£ al., 1985; Barlet, 1977; Cast £t al., 1979; Hibbs and 
Pounden, 1955; Hoffsis e_t al., 1978; Hove and Kristiansen, 1982; 
Jorgenson et al., 1978; Julien et al., 1977; Littledike and Korst, 
1979; Manston and Payne, 1964; Olsen ^  £l., 1972), but they act only 
to enhance intestinal calcium absorption (Braithwaite, 1978; Hove, 
1984). They do not increase bone resorption in the cow (Goff e£ al., 
1986) , probably because the hypercalcemia resulting from enhanced 
intestinal calcium absorption inhibits endogenous secretion of PTH 
necessary for bone resorption. In cows pretreated with vitamin D 
metabolites that develop parturient paresis, the endogenous 
1,25-(OH)2D response to hypocalcemia is inhibited (Littledike et al., 
1981). When vitamin D metabolites fail to prevent hypocalcemia, the 
resulting parturient paresis is often clinically more severe than 
normal parturient paresis (Littledike and Horst, 1979), suggesting 
that vitamin D compounds replace the cow's calcium homeostatic 
mechanisms rather than augment them. In the two cows (Nos. 3 and 4) 
in the present study that became hypocalcemic despite PTH infusion, 
plasma concentrations of PTH and 1,25-(OH)2D indicate that there is no 
suppression of endogenous PTH or 1,25-(OH)2D production in response to 
hypocalcemia. In contrast to the vitamin D compounds, it appears that 
exogenous PTH may augment the cow's homeostatic mechanisms rather than 
replace them. 
There was no evidence of renal toxicity during the administration 
of PTH to cows in these experiments. . Because PTH lowers plasma 
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phosphorus as it increases plasma calcium concentrations, the danger 
of metastatic calcification due to PTH administration should be less 
than that seen with the vitamin D compounds. However, the hypercal-
cemic activity of PTH dictates that the nephrotoxic potential of PTH 
needs to be carefully characterized. 
Parathyroid hormone may prove superior to vitamin D administra­
tion to prevent parturient paresis for several reasons. It is capable 
of stimulating bone resorption as well as intestinal calcium absorp­
tion at the time of parturition. Because it lowers plasma phosphorus, 
any hypercalcemia it induces should be less toxic than the hypercal­
cemia and hyperphosphatemia Induced by vitamin D compounds. Parathy­
roid hormone administration should present little risk to the consumer 
of milk or meat from treated animals as it is inactivated when in­
gested. These considerations and the results of this study lead us to 
conclude that PTH has potential for therapeutic intervention in dairy 
management. 
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Figure 1. Plasma calcium concentration of pregnant cows that 
received intravenous infusion of synthetic bovine 
PTH-(l-34) at a rate of 146 ug/h. Mean ± SE of four cows 
that received PTH between h 0-48 (0 0). Mean ± SE of 
three cows that received PTH between h 0-96 (0 0) 
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Figure 2. Plasma 1,25-(OH)jD concentration of pregnant cows that 
received intravenous infusion of synthetic bovine 
PTH-(l-34) at a rate of 146 ug/h. Mean ± SE of four cows 
that received PTH between h 0-48 (0 0). Mean ± SE of 
three cows that received PTH between h 0-96 (0 0) 
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PRETREATWENT PTH INFUSION PERIOO, 
DAY OF 24 HOUR URINE COLLECTION 
Figure 3. Daily total urinary hydroxyproline excretion before, 
during, and after treatment of three pregnant cows with 
synthetic bovine PTH-(l-34) at a rate of 146 pg/h for 96 
h. Mean ± SE. Astrisk denotes significantly different 
from pretreatment (P < 0.05) 
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Table 1. Plasma concentrations of minerals, 1,25-(0H)2D, PTH and OH 
OH-proline 24-h excretion rates in cows in late gestation 
146 yg PTH/h for 48 h (mean ± SE, n = 4) 
PTH infusion 
Control Day 1 Day 2 
Plasma concentrations 
Calcium 
(mg/dl) 
8.8 + 0.2 9.8 0.3* 11.6 ± 0 
Phosphorus 
(mg/dl) 
5.7 + 0.4 4.7 + 0.6* 4.0 ± 0 
Magnesium 
(mg/dl) 
2.10 + 0.09 2.78 + 
** 
0.11 2.57 ± 0 
1,25-(0H) 2 D  
(pg/ml) 
16.7 + 2.3 78.0 ± 
*** 
10.6 57.5 ± 1 
OH-Proline 
(pg/ml) 
1.23 + 0.14 1.41 + 0.25 1.54 ± 0 
PTH (ng/ml) 0.52 + 0.12 0.67 0.17 0.58 ± 0 
Urinarv excretion rates 
Calcium 
(mg/h) 
31.3 + t:9 6.5 + 
** 
1.3 7.7 ± 4. 
Phosphorus 
(mg/h) 
274 + 91 310 + 48 789 ± 61 
Magnesium 
(mg/h) 
21.6 ± 2.5 15.9 ± 3.4** 14.8 ± 2. 
OH-Proline 5.45 + 2.17 6.70 + 3.49 7.43 ± 4. 
* ** *x* 
P < 0.10. P < 0.05. P < 0.025 
OH-proline and urinary mineral and 
m before, during and after they received 
Recovery 
Day 1 Day 2 
9.7 ± 0.4 8.8 ± 0.3 
6.4 ± 0.9 5.9 ± 0.4 
*** ** 
1.70 ± 0.06 1.79 ± 0.01 
** 
± 13.2 21.0 ± 2.1 15.0 ± 1.0 
1.28 ± 0.19 1.48 ± 0.03 
0.46 ± 0.17 0.63 ± 0.01 
4.6* 140.7 ± 51.0* 78.0 ± 18.6 
** *** ,*** 
61 1059 ± 220 1222 ± 194 
2.3*** 17.8 ± 4.2 10.9 ± 3.3* 
4.20 5.81 ± 2.30 5.85 ± 2.14 
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Table 2. Plasma calcium, OH-proline, and 1,25-(0H)2D concentrations dur 
in cows in late gestation (mean ± SE) 
PTH infusion 
Control Day 1 Day 2 Day 3 
73 ug PTH/h for 96 h (n = 2) 
Calcium 
(mg/ml) 
1,25-(OH)2D 
(pg/ml) 
OH-?roline 
(ug/ml) 
146 ug PTH/h 
Calcium 
(mg/dl) 
OH-Proline 
(ug/ml) 
9.7 ± 0.1 
6.1 ± 1.6 
0 .86  ±  0 .20  
for 96 h fn = 3) 
8.2 ± 0.3 
32.1 ± 10.1 
0.98 ± 0.11 
9.4 ± 0.4 
20.5 ± 6.5 
1.00 ± 0.30 
9.0 ± 0.9 
113.3 ± 26.8 
1.10 ± 0.19 
9.6 ± 0.4 
20.5 ± 1.5 
0.89 ± 0.26 
11 .1  ±  0 .8*  
81.0 ± 21.5 
1.20 ± 0.19 
9.3 ± 0.0 
18.0  ± 10 .0  
0.95 ± 0.25 
13.1 ± 0.1* 
78.3 ± 26.8 
1.37 ± 0.16 
* AA **)'( 
P < 0.10. P < 0.05. P < 0.025 
wring the infusion of PTH for 96 h 
Recovery 
Day 4 Day 1 Day 2 
10.3 ± 0.4 9.7 ± 0.2 9.5 ± 0.8 
0 20.0 ± 5.0 11.0 ± 8.0 20.5 ± 9.8 
15 0.95 ± 0.35 1.15 ± 0.35 
L* 15.1 ± 1.5** 11.4 ± 1.0* 9.3 ± 0.4 
,8 63.7 ± 28.6 21.3 ± 5.1 8.7 ± 4.9 
16 1.54 ± 0.11 1.01 ± 0.01 0.94 ± 0.06 
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SUMMARY AND DISCUSSION 
Feeding cows a low calcium diet prior to parturition is an 
effective, but not universally practical, means of preventing parturi­
ent paresis. The effectiveness of this method is probably due to the 
stimulation of PTH and 1,25-dihydroxyvitamin D production prior to 
parturition which primes the bone and gut so that the calcium demands 
of lactation can be met. In Section I of this thesis, the effects of 
administration of 1,25-dihydroxyvitamin D and its analogues were 
examined. We found that vitamin D action on the intestine was the 
only positive prophylactic effect one could expect in the cow. These 
studies also determined that renal function can be impaired by higher 
doses of these compounds. In Section II of this thesis, we have 
demonstrated that 24-F-l,25-dihydroxyvitamin D can be successfully 
used to prevent parturient paresis in dairy cows and that it may be 
superior to 1,25-dihydroxyvitamin D for this purpose. However, the 
study also points out that the vitamin D compounds are only effective 
when given within a certain time frame prior to parturition. 
In Section III of this thesis, we have demonstrated that PTH can 
prevent parturient paresis in dairy cows. We have demonstrated that 
it acts by stimulating bone resorption, renal conservation of calcium 
and production of 1,25-dihydroxyvitamin D which, in turn, stimulates 
intestinal calcium absorption. We conclude that PTH has tremendous 
potential for prevention of parturient paresis. The obstacle to its 
use will be cost of the hormone and a method of delivery of the PTH. 
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